

Elimination of PknL and MSMEG_4242 in Mycobacterium smegmatis alters the character of the outer cell envelope and selects for mutations in Lsr2

Estalina Báez-Ramírez, Luis Querales, Carlos Andres Aranaga, Gustavo López, Elba Guerrero, Laurent Kremer, Séverine Carrère-Kremer, Albertus Viljoen, Mamadou Daffé, Françoise Laval, et al.

▶ To cite this version:

Estalina Báez-Ramírez, Luis Querales, Carlos Andres Aranaga, Gustavo López, Elba Guerrero, et al.. Elimination of PknL and MSMEG_4242 in Mycobacterium smegmatis alters the character of the outer cell envelope and selects for mutations in Lsr2. The Cell Surface, 2021, 7, pp.100060. 10.1016/j.tcsw.2021.100060 . inserm-03381892v1

HAL Id: inserm-03381892 https://hal.science/inserm-03381892v1

Submitted on 23 Nov 2021 (v1), last revised 18 Oct 2021 (v2)

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Contents lists available at ScienceDirect

The Cell Surface

journal homepage: www.sciencedirect.com/journal/the-cell-surface



Elimination of PknL and MSMEG_4242 in *Mycobacterium smegmatis* alters the character of the outer cell envelope and selects for mutations in Lsr2

Estalina Báez-Ramírez ^a, Luis Querales ^a, Carlos Andres Aranaga ^{a, 1}, Gustavo López ^{a, 8}, Elba Guerrero ^a, Laurent Kremer ^{b, 2}, Séverine Carrère-Kremer ^{b, 3}, Albertus Viljoen ^{b, 4}, Mamadou Daffé ^c, Françoise Laval ^c, Stewart Cole ^{d, 5}, Andrej Benjak ^{d, 6}, Pedro Alzari ^e, Gwenaëlle André-Leroux ^{e, 7}, Bill Jacobs ^f, Catherine Vilcheze ^f, Howard Takiff ^{a, g, *}

- a Laboratorio de Genétic Molecular, CMBC, Instituto Venezolano de Investigaciones Científicas (IVIC), Caracas, Venezuela
- b Institut de Recherche en Infectiologie de Montpellier, Centre National de la Recherche Scientifique UMR 9004, Université de Montpellier, Montpellier, France
- ^c Institut de Pharmacologie et de Biologie Structurale, Université de Toulouse, France
- d EPFL, Lauzanne, Switzerland
- ^e Unit of Structural Microbiology, Institut Pasteur, Paris, France
- ^f Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, USA
- ⁸ Shenzhen Nanshan CCDC, 7 Huaming Road, Nanshan, Shenzhen, China

ARTICLE INFO

Keywords:
Tuberculosis
Kinase
PknL
Lsr2
Biofilms
Mycobacterial envelope

ABSTRACT

Four serine/threonine kinases are present in all mycobacteria: PknA, PknB, PknB and PknL. PknA and PknB are essential for growth and replication, PknG regulates metabolism, but little is known about PknL. Inactivation of pknL and adjacent regulator MSMEG_4242 in rough colony M. smegmatis mc2155 produced both smooth and rough colonies. Upon restreaking rough colonies, smooth colonies appeared at a frequency of $\sim 1/250$. Smooth mutants did not form biofilms, showed increased sliding motility and anomalous lipids on thin-layer chromatography, identified by mass spectrometry as lipooligosaccharides and perhaps also glycopeptidolipids. RNA-seq and Sanger sequencing revealed that all smooth mutants had inactivated Isr2 genes due to mutations and different IS1096 insertions. When complemented with lsr2, the colonies became rough, anomalous lipids disappeared and sliding motility decreased. Smooth mutants showed increased expression of IS1096 transposase TnpA and MSMEG_4727, which encodes a protein similar to PKS5. When MSMEG_4727 was deleted, smooth pknL/ MSMEG 4242/lsr2 mutants reverted to rough, formed good biofilms, their motility decreased slightly and their anomalous lipids disappeared. Rough delpknL/del4242 mutants formed poor biofilms and showed decreased, aberrant sliding motility and both phenotypes were complemented with the two deleted genes. Inactivation of lsr2 changes colony morphology from rough to smooth, augments sliding motility and increases expression of MSMEG_4727 and other enzymes synthesizing lipooligosaccharides, apparently preventing biofilm formation. Similar morphological phase changes occur in other mycobacteria, likely reflecting environmental adaptations. PknL and MSMEG_4242 regulate lipid components of the outer cell envelope and their absence selects for lsr2 inactivation. A regulatory, phosphorylation cascade model is proposed.

[•] Corresponding author at: Laboratorio de Genétic Molecular, CMBC, Instituto Venezolano de Investigaciones Científicas (IVIC), Caracas, Venezuela. E-mail address: htakiff@gmail.com (H. Takiff).

 $^{^{\}rm 1}$ Current address: Facultad de Ciencias Básicas, Universidad Santiago de Cali, Cali, Colombia.

² INSERM, Institut de Recherche en Infectiologie de Montpellier, Montpellier, France.

³ Current address: Institute of Regenerative Medicine and Biotherapies (IRMB), University of Montpellier, INSERM, Montpellier, France.

⁴ Current address: Department for BioMedical Research, University of Bern, Switzerland.

⁵ Current address: Institut Pasteur, Paris, France.

⁶ Current address: Louvain Institute of Biomolecular Science and Technology, UCLouvain, Louvain-la-Neuve, Belgium.

⁷ Current address: INRA, Unité MalAGE, Jouy-En-Josas, France.

 $^{^{8}\,}$ In memorium.

1. Introduction

Serine/threonine protein kinases (STPK) in mycobacteria appear to be involved in regulating cell growth, division and metabolism (Molle and Kremer, 2010). Of the 11 STK in Mycobacterium tuberculosis, only four are ubiquitous in mycobacterial species: PknA, PknB, PknG and PknL. Knockouts or overexpression of the essential PknA and PknB alter the shape of the bacilli, probably due to their involvement in the formation of the cell wall (Kang et al., 2005). Of the remaining 9 STK in M. tuberculosis, only PknL belongs to the same clade as PknA and PknB (Narayan et al., 2007; Wehenkel et al., 2008), but few studies have addressed its possible functions (Refaya et al., 2016) (Naz et al., 2021). PknL was shown to phosphorylate an adjacent and divergently transcribed, putative transcriptional regulator, Rv2175c (Canova et al., 2008; Cohen-Gonsaud et al., 2009), reducing its ability to bind DNA, but it is unknown what stimulates this phosphorylation, what genes Rv2175c regulates or what role PknL plays in the biology of the bacteria. This transcriptional regulator and the position of the gene encoding it are conserved in most mycobacteria.

Nine of the 11 STKs in M. tuberculosis, including PknA, PknB and PknL, contain transmembrane regions (Av-Gay and Everett, 2000). Based on the eukaryotic model for serine/threonine and tyrosine kinases, it is thought that the extracellular regions of the M. tuberculosis STPK may perceive a signal that activates the kinase regions within the bacteria. The extracellular region of PknB contains four PASTA (Penicillin-binding proteins And Serine/Threonine kinase Associated) (Bellinzoni et al., 2019) domains that are thought to interact with the peptidoglycan or its muropeptide precursors (Bellinzoni et al., 2019) to regulate PknB autophosphorylation. Mycobacterial PknL's have < 10 extracellular amino acids beyond the transmembrane region, not enough for an extracellular receptor motif, and Mycobacterium tuberculosis PknL does not appear to be autophosphorylated but rather is phosphorylated by PknB and PknJ (Baer et al., 2014). However, the PknL in bacteria such as Corynebacterium glutamicum (Schultz et al., 2009) contain extracellular PASTA domains, suggesting that in these bacteria PknL could also be involved in regulating the synthesis of components of the cell wall or cell envelope.

To study the role of PknL in mycobacteria, we constructed strains of Mycobacterium smegmatis lacking functional copies of pknL $(MSMEG_4243)$ and the adjacent putative transcriptional regulator $MSMEG_4242$, as well as knockout strains containing intact, complementing copies of one or both genes. Some of the knockout strains formed smooth colonies distinct from the rough colony parent mc^2155 . The strains were characterized for phenotypes associated with the cell envelope, their lipid composition and transcriptomes.

2. Results

2.1. Construction of $\Delta pknL/\Delta MSMEG_4242$ mutants and complementing phenotypes

The 5' end encoding the N-terminal regions of the adjacent and divergently transcribed genes *pknL* and MSMEG_4242 were replaced with a kanamycin resistance cassette (Fig. 1A). In a first experiment, the double mutant was constructed in the rough colony parental strain *M. smegmatis mc*²155 as well as in strains containing integrating plasmid pYUB412int carrying either *pknL*, MSMEG_4242, or both genes (EB1 – 4, Fig. 1A & C,). Very few colonies were obtained, and all had a smooth morphotype (Fig. 2A). The deletion of both genes was initially confirmed by PCR amplification and restriction digests and subsequently by RNA-seq (data not shown). The mutant strains that contained plasmid pYUB412int with *pknL* and MSMEG_4242, separately or together, altered the morphology slightly, but the colonies remained smooth (Fig. 2A). The knockout experiment was repeated by another of the authors, using the same construct to eliminate both genes from the parent

 mc^2155 . In this second experiment many colonies were obtained, most of which were rough, but about 1/100 were smooth (Fig. 1B & D). Surprisingly, it was confirmed that the two genes had been eliminated in both smooth and rough colony morphotypes (data not shown). When the rough colony knock out strains were restreaked, smooth colonies appeared at a frequency of about 1/200 - 1/300 (Fig. 1D). In this second series of experiments, single knockouts of pknL and MSMEG_4242 were also constructed. Most of them showed the same rough phenotype as the double mutants and smooth colonies spontaneously appeared at the same frequency as they arose in the double mutant strains. The single knockout strains were not studied further. Both genes were also inserted, separately, into expression vector pMV261 and the plasmids were transformed into mc^2155 . The transformants showed no apparent alteration from the rough phenotype of the parent strain and were not studied further.

The smooth colony mutant strains were inoculated into liquid media and grew slightly, but not significantly slower than the mc^2155 parent (data not shown). The uncomplemented smooth colony mutant EB1 ($mc^2155 \Delta pknL/\Delta MSMEG_4242$) also formed longer bacilli (Fig. 2C & D) and appeared to show weaker acid-fast staining (Suppl. Fig. S1). Complementation with pknL and $MSMEG_4242$ restored both parental bacillus length and acid-fast staining. Strain EB1 was also two-fold more sensitive to rifampicin and cefoxitin than the parent mc^2155 (Table 1 and Fig. S2). The sensitivity to rifampicin was restored to that of the parent by complementation with just pknL, while complementation with both pknL and $MSMEG_4242$ were required to regain parental cefoxitin sensitivity.


2.2. Altered biofilms and sliding motility

Smooth colony morphotypes have been associated with alterations in the lipid composition of the outer cell envelope (Kocíncová et al., 2008), so we examined two phenotypes associated with cell envelope lipids – sliding motility (Recht and Kolter, 2001) and biofilm formation (Kocíncová et al., 2008). While the rough colony parent mc²155 forms strong biofilms and has moderate sliding motility, none of the smooth colony strains formed biofilms (Fig. 2E & 5), all had increased sliding motility (Fig. 2F & 5), and neither phenotype was restored to that of the parent by complementation with *pknL* and MSMEG_4242 (Table 2).

In contrast, the sliding motility of the rough $mc^2155 \Delta pknL/\Delta MSMEG_4242$ mutant was about half that of mc^2155 and was irregular and jagged, clearly different from the circular motility halos of all the other strains (Fig. 2F & 5). In addition, the rough $\Delta pknL/\Delta MSMEG_4242$ mutants could form only very weak, delayed biofilms. When the rough $\Delta pknL/\Delta MSMEG_4242$ was complemented with a plasmid containing pknL and $MSMEG_4242$, the strain formed biofilms only slightly weaker than the unmutated mc^2155 parent and its sliding motility showed a regular halo larger than that of the parent (Fig. 2E, 2F & 5 and Table 2). Thus, while the reduced motility and poor biofilms in the rough colony mutants were attributable to the absence of pknL and $MSMEG_4242$, the increased motility and lack of biofilms in the smooth mutants was not reversed by intact copies of these two genes.

2.3. Mutations in lsr2 were responsible for the smooth colony phenotype

RNA-seq of the smooth colony mutants (EB1-4) revealed that all contained mutations that inactivated the lsr2 gene (MSMEG_6092) (Chen et al., 2008; Gordon et al., 2010). EB1 ($\Delta pknL/\Delta MSMEG_4242$) had a new IS1096 insertion into lsr2, while EB2 ($\Delta pknL/\Delta 4242$ -MSMEG_4242) had a different new IS1096 insertion into the lsr2 gene. RNA-seq showed an increase in the expression of IS1096 transposase tnpA from some of the IS1096 insertions in EB1 and EB2 (Table 3). Strain EB3 ($\Delta pknL/\Delta 4242$ -pknL) had a one base, frameshifting insertion into lsr2 (Fig. 3), while strain EB4 ($\Delta pknL/\Delta MSMEG_4242$ – $pknL/MSMEG_4242$), showed the same frameshifting but only in a mi-






Fig. 1. A. Strategy for deleting both MSMEG_4242 (a putative transcriptional regulator) and MSMEG_4243 (*pknL*). A kanamycin resistance cassette replaced the 5′ terminal of both genes along with the intergenic region. This was inserted into plasmid pPR27, which carries a temperature sensitive mycobacterial origin of replication, the *sacB* gene and a gentamycin resistance cassette (Pelicic et al., 1997). **B.** Strategy for construction of strains lacking either MSMEG_4242 or MSMEG_4243 (*pknL*). **C.** Schematic diagram of strains originating from the first experiment to knock out both MSMEG_4242 and MSMEG_4243 (*pknL*) - EB1 – 4 and derivatives.**D.** Schematic diagram of strains originating from the second experiment to knock out both genes.

nority of RNA-seq reads. This frameshifting mutation was also present in a small minority of reads from wt parent mc²155 and was seen in three reads from double knockout strain EB1. With successive passaging and restreaking, strain EB4 eventually reverted to a rough colony morphology. RNA-seq also showed increased expression of the IS1096 transposase *tnpA* from some of the other IS1096 insertions in EB1 and EB2 (Table 3), but no further IS1096 insertions were found.

PCR amplification and Sanger sequencing showed that all smooth colony mutants isolated in the second knockout experiment, or smooth colonies that appeared spontaneously on restreaking these rough colony double mutants, also contained mutated lsr2 genes, including IS1096 insertions, a frameshift due to a nucleotide deletion and a mutation substituting an alanine for an aspartic acid at amino acid 35 (D35A) (Fig. S4). In contrast, the lsr2 genes were intact in all rough colony mutants. When strain EB1 ($\Delta pknL/\Delta MSMEG_4242/\Delta lsr2$) was transformed with a plasmid carrying an intact copy of lsr2, the colony morphology reverted to rough.

2.4. Analysis of cell envelope lipids

Thin-layer chromatography (TLC) of smooth colony strain EB1 showed anomalous bands, predominantly in the polar fraction, that disappeared when the strain was transformed with a plasmid carrying lsr2 and became rough (Fig. 4A & B.). These anomalous bands were not present on TLC of the rough colony $\Delta pknL/\Delta MSMEG_4242$ strains.


Mass spectrometry (MS) of cell wall lipids of the uncomplemented smooth colony mutant EB1 revealed anomalous peaks that were not present in parent strain mc²155 (Fig. 4C & D). The mass range of the peaks suggested that they were likely lipooligosaccharides A (LOS A) and C (LOS C) (Etienne et al., 2005), but there were also anomalous peaks in the size range of glycopeptidolipids (GPLs) (Etienne et al., 2005).


2.5. Elimination of MSMEG_4727 restored rough colony morphology in strain EB1.

The RNA-seg study of smooth colonies EB1 - EB3 also showed a marked increase in the transcripts of MSMEG 4727 and other downstream genes implicated in the synthesis of LOS (Table 3) (Etienne et al., 2009; Colangeli et al., 2007). MSMEG_4727 encodes a polyketide synthase similar to the PKS5 associated with the production of LOS in smooth colony Mycobacterium canetti. It was shown to be inactivated in rough colony M. canetti strains and M. tuberculosis (Boritsch et al., 2016). When the MSMEG_4727 gene was eliminated in strain EB1 to create EB1- $\Delta 4727$ ($\Delta pknL/\Delta 4242/\Delta lsr2/\Delta 4727$), the colony morphology reverted to rough, although slightly different from the parent mc^2155 (Figs. 5 and S3). The EB1- Δ 4727 strain was capable of forming normal biofilms and its sliding motility was reduced but still about 50% greater than that of parent mc2155 (Fig. 2E, 2F, 5 and Table 2). When MSMEG_4727 was eliminated from parent strain mc²155, the resulting mutant could form normal biofilms but the sliding motility was reduced by nearly half. In contrast, when MSMEG_4727 was deleted from an lsr2 mutant obtained by transposon mutagenesis of mc2155 strain NJS20 (Colangeli et al., 2007); there was no motility and the strain could not form biofilms (Kocíncová et al., 2008). These results confirm that the inactivation of lsr2 in the smooth colony pknL/4242 mutants led to increased production of LOS from the MSMEG_4727 synthesis pathway, which prevented the formation of biofilms but contributed to motility.

3. Discussion

This study was undertaken to explore the role of PknL in mycobacterial biology but led to unexpected results. All smooth colony $pknL/MSMEG_4242$ knockout strains harbored lsr2 genes that had been mutated by frameshifts, amino acid substitutions or IS1096 insertions, perhaps associated with the increased transcription of transposase TnpA seen on RNA-seq. The smooth mutants had two sets of phenotypes – those stemming from the lack of PknL/MSMEG_4242 and those caused by absence of Lsr2. The phenotypes of the smooth triple mutant smooth EB1 strain ($\Delta pknL/\Delta MSMEG_4242/\Delta lsr2$) that were reversed








Fig. 2. Origins and phenotypes of the mutant strains in this study. A. In the first experiments, pknL and MSMEG_4242 were inactivated in wt mc²155 and in mc²155 containing integrating plasmid pYUB412int carrying either or both genes. B. The second experiment repeated the first, with the same pPR27 construct, but only in wt mc²155. The construction of the $\Delta lsr2$ strain was described previously (Colangeli et al., 2007). Fig. 2 Phenotypes of mutant strains. Colony Morphology of wt and mutant strains obtained in the first knockout experiment Colony Morphology of other strains in this study. Histogram showing measured length of 100 bacilli of each strain: wt, mc²155; KO, EB1- mc²155 $\Delta pknL/\Delta MSMEG_4242$; KO + 42, EB2 $\Delta pknL/\Delta MSMEG_4242$ + pYUB412intMSMEG_4242; KO + pknL, EB3 $\Delta pknL/\Delta MSMEG_4242$ + pYUB412intpknL. Histogram of the average lengths of 100 bacilli shown in C. Asterisk (*) indicates that the difference is statistically significant, P \leq 0.05. Biofilms of the different strains, in duplicate. The +'s or -'s indicate the quality of the biofilm. Sliding motility of the different strains, in duplicate.

with a plasmid carrying *pknL/MSMEG_4242* were: longer bacilli; poor acid-fast staining; and increased sensitivity to rifampicin and cefoxitin (Table 1 & Fig. S2). The phenotypes complemented by intact copies of *lsr2* included the smooth colony morphology, the inability to form biofilms, increased sliding motility and additional lipid species, probably LOS-A, LOS-C and subfamilies of GPL (Etienne et al., 2005). These are reminiscent of the phenotypes of the original *M. smegmatis* strain

ATCC607 that were lost when it evolved into variant mc^2155 (Etienne et al., 2005). Eliminating the PKS enzyme MSMEG_4727 in EB1(mc^2155 $\Delta pknL/\Delta MSMEG_4242/\Delta lsr2$) reversed the smooth colony morphotype and reduced motility, but when the single lsr2 mutant was complemented with lsr2, it still could not form biofilms. This single lsr2 mutant strain was obtained from another lab (Colangeli et al., 2007) and may

Table 1
Sensitivity of mutants and complemented mutants to Rifampicin and Cefoxitin.

	Rifampi	cin	Cefoxitin		
	32 ug/ml	64 ug/ml	12.5 ug/ml	25 ug/ml	
mc ² 155	+ +	++	+ +	++	
Del pknL/4242/lsr2 smooth	+ +		++		
Del pknL/4242/lsr2 smooth (4242)	+ +		+ +	+	
Del pknL/4242/lsr2 smooth (pknL)	+ +	++	++		
Del pknL/4242/lsr2 smooth (pknL/4242)	++	+ +	+ +	++	
Del <i>lsr2</i>	++	+			
Del lsr2 (lsr2)	+ +	++			
Del pknL/4242 rough	++	++			
Del $pknL/4242$ rough ($pknL/4242$)	+ +	+ +			

Table 2Genotypes and phenotypes of mutant strains.

	pknL/4242	lsr2	4727	Biofilm	Motility (in mm*)	Morphology
A: mc ² 155	Yes	Yes	Yes	+++	38	rough
D: EB1	No	No	Yes	-	65	smooth
E: EB1 + p4242/4243	yes	No	Yes	-	68	smooth
I: EB1-Δ4727	No	No	No	+++	55	rough
H: mc ² 155 Δ4727	Yes	Yes	No	+++	20	rough
F: Δ4242/4243(R)	No	Yes	Yes	+	20#	rough but altered
G: Δ4242/4243 + p4242/4243	yes	Yes	Yes	++	50	rough
B: ∆lsr2	Yes	No	Yes		48	smooth
C: $\Delta lsr2 + plsr2$	Yes	yes	Yes		28	rough
J: Δ <i>lsr</i> 2-Δ4727	Yes	No	No	-	4	very rough

- *, Motility measured as millimeters of halo diameter.
- #, irregular halo.
- + + + Mature floating biofilm.
- + + Mature biofilm.
- + Slow formation of biofilm.
- Abnormal biofilm.
- - No biofilm.

have acquired additional genetic changes, which appear to be frequent in *M. smegmatis* strains(Kocíncová et al., 2008; Etienne et al., 2005).

To fit these results into a regulatory model, we compared our findings with previously published studies. PknL was shown to be incapable of autophosphorylation but was phosphorylated by PknB and PknJ and colocalized with PknB to the bacillus poles and midplane septa (Baer et al., 2014), sites thought to be related to bacterial replication. A recent study found that a strain of M. tuberculosis lacking PknL showed decreased survival in macrophages and the spleens of infected mice, and also showed increased the Minimum Inhibitory Concentrations (MICs) for isoniazid and ethambutol (Naz et al., 2021). We found no difference in resistance to isoniazid, but a two-fold increase in susceptibility to rifampicin and cefoxitin. These are large molecules, so changes in their susceptibility could reflect changes in cell wall permeability(Kolodziej et al., 2021). It was reported that the absence of Lsr2 in M. smegmatis increases susceptibility to rifampicin and nalidixic acid(Kolodziej et al., 2021), and that overexpression of PknB increased susceptibility to rifampicin and vancomycin(Le et al., 2020) likely due to alterations of the cell envelope. Zeng et al. found that depletion of either PknA or PknB from M. tuberculosis reduced the MICs for cephalosporins, carbapenems and rifampicin (Zeng et al., 2020). We found that a strain with a mutated lsr2 had increased susceptibility to rifampicin that was

complemented with a parental copy of lsr2 (Table 1). However, there was a greater increase in susceptibility in smooth strains lacking PknL and MSMEG_4242 in addition to Lsr2, and the rifampicin susceptibility returned to that of the parent when these strains were complemented only with pknL and MSMEG_4242 (Table 1 and Suppl. Fig. 2). The lack of an increase in susceptibility in the rough $\Delta pknL/\Delta MSMEG_4242$ mutants suggests that the deletion of PknL and MSMEG_4242 has a synergistic effect with Lsr2 mutations in altering the cell envelope. It has been reported that Lsr2 also controls pigment in M. smegmatis (Kocíncová et al., 2008); but although some of the mutant strains had altered pigmentation, we did not analyze this phenotype.

In a study in *M. tuberculosis* using an antisense strategy, a strain with a PknL knockdown showed no change in colony morphology but, similar to our results, the mutant bacilli grew slower and were \sim 0.8 µm longer. They also found that the knockdown strain had lower viability over time but increased resistance to pH 5.5, SDS and lysozyme (Refaya et al., 2016). In contrast, a very recent study described shorter and wider bacilli in an *lsr2* mutant strain(Kolodziej et al., 2021).

Several publications have addressed Lsr2, a nucleoid-associated protein that has been associated with cell cycle(Kolodziej et al., 2021) and is essential in M. tuberculosis (Colangeli et al., 2007; Kolodziej et al., 2021; Kolodziej et al., 2021) (Chen et al., 2008; Gordon et al., 2010) but not in M. smegmatis. The genes that Lsr2 appears to regulate – its regulon, is broad and overlaps with the PknB regulon (Algaseer et al., 2019). It was previously observed that smooth colonies of M. smegmatis appear as spontaneous variants of M. smegmatis ATCC607, the parent strain of mc2155, as a result of insertions of IS1096 into lsr2 (Kocincová et al., 2008). These hypermotile variants, which are unable to form biofilms, appeared in a starvation experiment with a relA (stringent response) mutant at a frequency of approximately 10⁻⁴ (Arora et al., 2008), higher than the expected frequency of about 10⁻⁶. In our rough colony pknL/ MSMEG_4242 knockout mutants, the insertions, deletions, amino acid substitutions or IS1096 insertions in lsr2 occurred at a frequency of nearly 10⁻², which is unexpectedly high but perhaps partially explained by the increased transcription of IS1096 transposase TnpA. The growth rate, bacillary length and rifampicin sensitivity of lsr2 smooth colony mutants were not previously reported to be different from those of the parent strains, although similar to our smooth strains, they showed increased sliding motility (Colangeli et al., 2007; Arora et al., 2008; Chen et al., 2006). Smooth colony lsr2 mutant strains also had anomalous lipid species, generally polar lipids identified as GPLs (Colangeli et al., 2007) that were present in greater amounts than in the parent strains (Kocíncová et al., 2008). GPLs have been shown to be essential for sliding motility (Recht et al., 2000). One study (Chen et al., 2006) found that two apolar mycolyl-diacylglycerols (MDAGs) were lost in an mc²155 strain with an insertion in *lsr2*, but a recent study convincingly showed that LOS are produced in *lsr2* mutants(Kolodziej et al., 2021).

Apparently, M. smegmatis can have many types of variants. The original ATCC607, from which the transformation competent mc2155 was selected (Snapper et al., 1990), could not form biofilms and had low motility (Etienne et al., 2005), but a strain with an IS1096 inserted into lsr2 showed increased production of GPLs, increased motility and could not form biofilms. A similar phenotype was found in strains with IS1096 insertions upstream of MSMEG 0400, the first gene of the mps operon, whose encoded enzymes synthesize GPLs, and transcription of this operon was increased. Genome sequencing found that mc2155 has an IS1096 insertion into this promoter region(Kocíncová et al., 2008). It was reasoned that Lsr2 negatively regulates the synthesis of GPLs by the mps gene cluster (Kocíncová et al., 2008) but the IS1096 insertions abolished the Lsr2 regulatory site. The RNA-seq studies of the smooth colony mutant EB1, which lacks an intact lsr2 gene, did not show an increase in the transcription of the genes in the mps cluster, perhaps because it is already highly expressed in mc2155 (Kocíncová et al., 2008) due to the IS1096 insertion upstream of the mps operon that eliminated the Lsr2 binding site.

Table 3 RNA-seq results of strains EB1, EB2 and EB3 vs EB4 and/or wt mc^2 155

	RNA-seq results of strains EB1, EB2 and EB3 vs EB4 and/or wt mc ² 155								
MAMINE_1128 9.31 9.32 0.00 0.00 6.22 9.31 4.59 Prohibition protein MAMINE_1219 3.46 9. Prohibition protein MAMINE_1219 3.46 9.11 0.00 0.00 4.41 4.3 4.3 6.69 prohibition protein MAMINE_1219 3.46 9.10 0.00 0.00 4.41 4.3 4.3 4.3 0 million containing protein MAMINE_1219 3.46 9.10 0.00 0.00 4.40 4.50 0.00 0.00 4.40 4.50 0.00 0.0		EB1+2	2+3 vs. E	B4+W	/T	EB1 vs. WT	EB2 vs. WT	EB3 vs. WT	
MASHING_1241 33,47 375 0.00 0.00 7.16 325 6.09 prospholysine to deman-containing protein MASHING_1247 276 379 0.00 0.00 0.00 4.01 4.01 4.05 4.05 1.05	gene	foldChange	log2FC	pval	padj	log2FC	log2FC	log2FC	product
MSMEQ_1289	MSMEG_1128	90.83	6.51	0.00	0.00	6.22	5.83	4.49	hypothetical protein
MSMINE_1240 1256 479 0.00 0.00 5.15 5.86 5.479 MSMINE_1247 11.63 421 0.00 0.00 4.30 4.20 4.20 4.35 0.00 0.00 4.30 4.20 4.20 4.35 0.00 0.00 4.30 4.20 4.35 0.00 0.00 4.30 4.20 4.35 0.00 0.00 4.30 4.20 4.35 0.00 0.00 4.30 4.20 4.35 0.00 0.00 4.30 4.20 4.30	MSMEG_1241	53.87	5.75	0.00	0.00	7.16	7.35	6.09	phospholipase D domain-containing protein
Missing 147 18.5 4.21 0.00 0.00 5.06 5.12 4.42 4.55 0.00 1.00	MSMEG_1129	34.45	5.11	0.00	0.00	4.41	4.35	4.31	D-amino-acid dehydrogenase
Monte, 1974 18.53 4.21 0.00 0.00 4.90 4.92 4.95 0.072.256 domain-containing protein Monte, 1974 12.41 1.24 1.26 0.00 0.00 4.91 4.10 3.38 0.072.256 domain-containing protein Monte, 1970 11.21 1.24 0.00 0.00 4.91 1.25									
MSMG_1246 15.77 1.97 0.00 0.00 4.01 4.10 1.38 hypothetical protein									
MSMEG_5709 1.128 3.49 0.00 0.00 3.58 4.65 3.65 3.67									
Monte, 5798 1.72 3.49 0.00 0.00 3.88 4.10 3.70 0.075 0.05									**
MSMEG_5709	_								
MAMIG. 173	_								
MAMEE_1732 9.14 3.2 0.11 1.00 3.65 2.83 1.55 Mysocypet transferase family protein Mysoches 1.05 Mysocypet 1.05 Mysocyp	_								
Martic 1739 3.19 0.0 0.39 3.36 2.91 1.74 Importance									
MSMCE_1315	_								
MSMGC_9459	_								
MSMEG_1497	MSMEG_4728	8.73	3.13	0.00	0.25	3.73	2.95	2.40	condensation domain-containing protein
MSMIG. 5279 8.03 3.10 0.00 0.02 1.99 3.13 2.84 MING. G170 7.99 3.00 0.00 0.00 3.96 4.14 3.88 \$spA_Epé domain-containing protein MSMIG. 5710 7.99 3.00 0.00 0.00 3.95 4.14 3.88 \$spA_Epé domain-containing protein MSMIG. 4727 7.88 2.89 0.00 0.00 3.35 2.30 3.10 MSMIG. 2822 7.81 2.97 0.00 0.01 2.52 2.86 5.20 transposas, truncation MSMIG. 5827 7.60 2.94 0.00 0.13 3.17 3.13 1.85 MSMIG. 5937 7.60 2.94 0.00 0.01 2.52 2.86 5.20 transposas, truncation MSMIG. 1247 7.33 2.81 0.00 0.00 3.85 3.50 3.50 3.42 MING. 1247 7.75 2.27 0.01 1.00 2.93 3.85 3.50 3.42 MING. 1247 7.75 3.28 1.00 0.00 0.00 3.85 3.50 3.42 MING. 1247 7.75 3.28 1.00 0.00 0.00 3.85 3.50 0.00 0.00 1.85 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.0	MSMEG_5460	8.43	3.08	0.00	0.00	2.53	3.07	2.65	hypothetical protein
MSMG S79 803 30 00 00 00 396 4.14 8.38 Espa, Espa 6main-containing protein	MSMEG_5874	8.39	3.07	0.38	1.00	-0.87	4.70	1.07	tRNA-Thr
MSMES 5710 7.99 3.00 0.00 0.00 3.96 4.14 3.88 Espa 6.psp downlar-containing protein MSMEG 2822 7.82 2.97 0.00 0.00 3.15 3.23 3.10 transposase, truncation MSMEG 3927 7.89 2.94 0.00 0.01 2.52 2.86 2.00 most of the protein MSMEG 397 7.55 2.29 0.01 1.00 2.93 2.44 1.00 protein MSMEG 1287 7.33 2.81 0.00 0.00 3.85 3.50 3.42 Mporthetical protein MSMEG 1288 6.80 2.75 0.35 1.00 0.02 2.93 2.14 1.12 reprotein MSMEG 378 6.80 2.73 0.50 0.00 2.25 2.35 1.00 0.042 2.93 2.14 1.12 2.05 1.00 0.01 2.65 3.00 0.00 1.00 2.05 1.00 2.05 1.00 2.00 1.00 1.00	MSMEG_3429	8.31	3.06	0.01	0.74	3.87	3.89	1.91	O-acyl transferase
MSMEC, 4727 7, 89 2,98 0.00 0.00 3,30 2,90 2,34 mycocrosic acid synthase MSMIC, 4282 7,81 2,96 0.00 0.01 3,15 3,23 3,10 transcriptional regulatory protein MSMIC, 5975 7,69 2,90 0.00 0.13 3,17 3,13 1,18 60 7,67 7,59 2,90 0.00 0.3 3,50 3,60 3,42 hypothetical protein MSMIC, 1278 6,80 2,76 0.00 0.07 3,31 3,50 2,23 type lif restriction enzyme, res subunit MSMIC, 4716 6,73 2,75 0.05 1.00 0.42 2,33 0.06 18*HA-Arg MSMEG, 4737 6,66 6,72 0.00 0.01 2,25 3,30 2,35 bacterioferitin MSMEG, 2826 6,49 2,70 0.00 0.01 2,27 3,69 0.09 1.71 1.71 1.71 1.71 1.71 1.71 1.71 1.71 1.71 </td <td>_</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	_								
MSMEG_2822 7,82 2,97 0.00 0.01 2,52 2,86 2,50 Urrapsocase, Truncation (MSMEG_472 7,81 2,96 0.00 0.01 2,52 2,86 2,50 Urrapsocase, Truncation (MSMEG_5957 7,69 2,94 0.00 0.01 3,31 3,13 18,5 GDP-manuse 6-dehydrogenase AlgD (MSMEG_1707 7,03 2,81 0.00 0.00 3,86 3.50 3,82 Phypothetical protein (MSMEG_1287 7,03 2,81 0.00 0.00 3,86 3.50 3,82 Phypothetical protein (MSMEG_1287 6,70 0.00 0.07 3,13 3,50 0.06 18N-A-// ₁₈ 0.00 1,00 0.02 3,00 0.01 1,00 0.02									
MSMEG 4924 7,81 2,96 0.00 0.01 3.37 3.13 1.85 GOP—manuse 6-delythydrogense AigD MSMEG 470 7,55 2,92 0.01 1.00 0.00 3.85 3.50 3.42 hypothetical protein MSMEG 128 6.80 2,76 0.00 0.07 3.31 3.50 2.23 type lil restriction enyme, res subunit MSMEG 128 6.68 2,76 0.00 0.42 2.39 2.14 1.71 apple Construction enyme, res subunit MSMEG 471 6.66 2,74 0.00 0.01 1.31 0.72 4.70 0.00 1.01 1.11 0.72 4.70 NAMEG 3564 6.69 2.70 0.00 0.01 2.25 3.53 3.40 1.85 MARC 3564 6.64 2.59 0.00 0.01 2.27 3.69 0.93 1.84 4.70 1.70 thNA-day MSMEG 2826 6.44 2.59 0.00 0.01 4.78 4.43 4.92 1.70 1.70 <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>									
MSME6_1957 7, 69 2.94 0.00 0.13 3.17 3.12 1.85 GOP-mannose -derlydrogenase AlgO MSME6_1247 7,03 2.81 0.00 0.00 3.85 3.50 3.22 1 hypothetical protein MSME6_1278 6.60 2.75 0.35 1.00 0.04 3.50 2.23 1 hypothetical protein MSME6_1470 6.66 2.73 0.50 1.00 1.31 0.72 4.70 MSME6_1747 6.66 2.73 0.50 1.00 1.31 0.72 4.70 MSME6_1747 6.66 2.73 0.50 1.00 1.21 2.53 3.00 2.95 18M-Avg MSME6_1566 6.47 2.69 0.00 0.00 2.27 3.69 3.95 1.70 NAM-Lys NAM-Lys <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>									
MSMEG_1238 1.20	_								
MSME6_1247 7, 70, 3 2.81 0.00 0.00 7, 31, 31 3.50 2.23 Npothetical protein MSME6_1236 6.80 2.75 0.35 1.00 0.42 2.33 2.14 1.71 adv/CaA synthetical protein MSME6_1741 6.88 2.74 0.00 0.42 2.33 2.14 1.71 adv/CaA synthetical protein MSME6_1747 6.66 2.73 0.00 1.00 1.31 0.72 4.70 NSME6_1747 6.66 2.73 0.00 1.00 1.31 0.72 4.70 NSME6_1747 6.66 6.47 2.69 0.50 1.00 2.27 3.69 2.95 Date-inferritin RNA-Gly MSME6_2826 6.49 2.69 0.00 0.52 3.33 3.40 1.86 NSME6_2826 6.44 2.69 0.00 0.52 3.33 3.40 1.86 NSME6_1223 6.58 2.67 0.41 1.00 1.39 4.14 0.77 NSME6_1223 6.58 2.67 0.41 1.00 1.06 3.70 0.07 NSME6_1223 5.34 2.57 0.00 0.04 3.34 2.86 1.70 NSME6_123 5.94 2.57 0.00 0.34 3.14 2.86 1.70 NSME6_1535 5.57 2.57 0.00 0.34 3.14 2.86 1.70 NSME6_5459 5.57 2.50 0.00 0.56 2.10 1.74 1.97 NSME6_5459 5.57 2.50 0.00 0.56 2.10 1.74 1.97 NSME6_5459 5.57 2.50 0.00 0.08 2.68 2.21 2.00 NSME6_535 5.44 2.40 0.00 0.03 3.31 2.27 2.00 NSME6_5459 5.36 2.24 0.00 0.03 3.31 2.27 2.00 NSME6_555 5.55 2.47 0.00 0.08 3.68 2.97 2.72 S.55 NSME6_1337 5.34 2.42 0.41 1.00 1.14 3.87 0.78 NSME6_1337 5.34 2.42 0.41 1.00 1.14 3.87 0.78 NSME6_1337 5.34 2.44 0.00 0.02 3.47 2.50 NSME6_1337 5.34 2.44 0.00 0.02 3.44 2.46 3.82 NSME6_1337 5.34 2.44 0.00 0.03 3.34 2.44 2.46 3.82 NSME6_1357 NSME6_1	_								
MSMEG, 1238 6,80 2,76 0.00 0.07 3,13 3,50 0.05 15NA-Arg MSMEG, 4731 6,68 2,74 0.00 0.42 2,93 2,14 1,17 accordance MSMEG, 1747 6,66 2,73 0.00 0.01 2,85 3,30 2,35 RNA-Dynherase sigma-70 factor MSMEG, 3564 6,49 2,70 0.00 0.01 2,85 3,30 2,35 RNA-Morror MSMEG, 2626 6,44 2,69 0.00 0.2 3,53 3,40 1,86 PIN_8 domain-containing protein MSMEG, 5758 6,35 2,67 0.41 1,00 -1,19 4,14 0.77 RNA-Gly MSMEG, 1239 5,94 2,53 0.00 0.1 4,78 4,43 4,52 MSA-Ara M									
MSMEG_4708 6,73 2,75 0.35 1.00 0.42 2.93 2.14 1.71 acyl-CoA symthetase MSMEG_1747 6,66 2,73 0.50 1.00 1.31 0.72 4.70 NAMEG_5364 6,69 2.70 0.00 0.01 2.85 3.30 2.35 but-certofferritin MSMEG_586 6.49 2.09 0.00 0.52 3.53 3.80 1.88 PNR_986 description PNR_986 PNR_986 6.00 0.52 3.53 3.40 1.88 PNR_986 description PNR_986 PNR_986 6.00 0.00 0.01 4.78 4.43 4.52 PNR_990 thetical protein PNR_990 thetical protein <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></td<>									
MSMEG_173T 6.68 2.74 0.00 0.42 2.93 2.14 1.71 acyl-CoA synthetase MSMEG_1364 6.69 2.79 0.00 0.01 2.65 3.30 2.35 banker RNA polymerase sigma-70 factor MSMEG_2826 6.44 2.69 0.50 1.00 -2.27 3.69 -0.95 IRNA-Gyner MSMEG_1578 6.35 2.67 0.41 1.00 -1.39 4.14 0.77 1RNA-Lys hybrothetical protein MSMEG_1223 6.18 2.63 0.00 0.01 4.78 4.43 4.52 hybrothetical protein MSMEG_1523 5.94 2.57 0.00 0.43 3.14 2.86 1.70 hybrothetical protein MSMEG_3599 5.67 2.50 0.00 0.55 2.10 1.74 1.97 hybrothetical protein MSMEG_5092 5.64 2.50 0.00 0.5 2.10 1.74 1.97 hybrothetical protein MSMEG_5135 5.42 2.0 1.0									
MSMEC_3564 6.49 2.70 0.00 0.01 2.65 3.30 2.31 NAX polymerase sigma-70 factor MSMEG_4676 6.47 2.69 0.50 1.00 -2.27 3.69 0.95 1.00 1.22 3.69 0.95 1.00 <td>_</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	_								
MSMEG_3564 6.49 2.70 0.00 0.11 2.65 3.30 2.35 MSMEG_4676 6.47 2.69 0.50 1.00 -2.27 3.69 -0.95 tRNA-Gly MSMEG_2826 6.44 2.69 0.00 0.52 3.53 3.40 1.86 PNLB_8 domain-containing protein MSMEG_1233 6.18 2.65 0.00 0.01 4.78 4.14 0.77 tRNA-Gly MSMEG_1233 5.94 2.57 0.00 0.34 3.14 2.86 1.70 0.07 tRNA-Gly MSMEG_3579 5.79 2.53 0.00 0.13 3.65 3.05 2.48 1.70 hypothetical protein MSMEG_5459 5.67 2.50 0.00 0.56 2.10 1.74 1.97 hypothetical protein MSMEG_5585 5.47 0.00 0.08 2.68 2.21 2.02 hypothetical protein MSMEG_5092 5.36 2.42 0.00 1.14 3.87 2.49 0.48 <td>_</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	_								
MSMEG_28676 6.47 2.69 0.50 1.00 -2.27 3.69 -0.95 RRNA-Gly MSMEG_2758 6.35 2.69 0.01 1.39 4.14 1.07 ItRNA-Lys MSMEG_478 6.11 2.61 0.04 1.00 1.03 4.43 4.52 hypothetical protein MSMEG_478 6.11 2.61 0.44 1.00 1.06 3.70 1.07 hypothetical protein MSMEG_1237 5.94 2.57 0.00 0.34 3.14 2.86 1.70 hypothetical protein MSMEG_5459 5.67 2.50 0.00 0.5 2.10 1.74 1.97 hypothetical protein MSMEG_5135 5.55 2.47 0.00 0.08 2.68 2.21 0.01 1.74 hypothetical protein MSMEG_5355 5.44 2.42 0.02 1.00 3.36 2.49 0.48 hypothetical protein MSMEG_1315 5.35 2.42 0.41 1.00 -1.89	_								
MSNEG_5758 6.35 2.67 0.41 1.00 -1.39 4.14 0.77 RNA-Lys NAN-Lys									
MSNEG_5758 6.35 2.67 0.41 1.00 -1.39 4.14 0.77 RNA-Lys NAN-Lys	MSMEG 2826	6.44	2.69	0.00	0.52	3.53	3.40	1.86	PIN 8 domain-containing protein
MSNEG_1223 6.18 2.63 0.00 0.01 4,78 4.43 4.52 Mypothetical protein MSMEG_1253 5.94 2.57 0.00 0.34 3.14 2.86 1.70 Mypothetical protein MSMEG_5459 5.67 2.50 0.00 0.56 2.10 1.74 1.97 Mypothetical protein MSMEG_5459 5.67 2.50 0.00 0.56 2.10 1.74 1.97 Mypothetical protein MSMEG_5459 5.67 2.50 0.02 1.00 2.75 3.28 1.29 Mypothetical protein MSMEG_5535 5.44 2.40 0.01 3.36 2.49 0.48 Mypothetical protein MSMEG_5535 5.44 2.40 0.01 3.31 2.72 1.92 Mypothetical protein MSMEG_5535 5.44 2.00 0.13 3.11 2.53 MAR 6.14 MAR 4.82 Mypothetical protein MSMEG_5535 5.44 2.00 0.01 3.41 <	_								· · · · · · · · · · · · · · · · · ·
MSMEG_4178 6.11 2.61 0.44 1.00 -1.06 3.70 0.07 RNA-Asn MSMEG_3579 5.79 2.53 0.00 0.34 3.14 2.86 1.70 MSMEG_5379 5.79 2.50 0.00 0.56 2.10 1.74 1.97 hypothetical protein MSMEG_599 5.67 2.50 0.00 0.56 2.10 1.74 1.97 hypothetical protein MSMEG_599 5.67 2.47 0.00 0.08 2.68 2.21 2.02 MSMEG_5077 5.36 2.42 0.00 0.13 3.11 2.72 1.92 MSMEG_1337 5.34 2.42 0.00 0.13 3.11 2.72 1.92 hypothetical protein hypothetical protein MSMEG_1337 5.34 2.42 0.01 0.02 3.42 3.11 2.53 hypothetical protein MSMEG_1399 5.03 2.41 0.00 0.02 3.42 3.11 2.53 hypothetical protei									
MSMEG_1253									
MSMEG_5459 5.67 2.50 0.00 0.56 2.10 1.74 1.97 hypothetical protein MSMEG_5135 5.55 2.47 0.00 0.08 2.68 2.21 2.02 hypothetical protein MSMEG_5355 5.44 2.44 0.09 1.00 3.36 2.49 0.48 hypothetical protein MSMEG_5090 5.36 2.42 0.00 0.13 3.11 2.72 1.92 hypothetical protein MSMEG_1337 5.34 2.42 0.01 0.13 3.11 2.72 1.92 hypothetical protein MSMEG_3163 5.30 2.41 0.00 0.08 3.68 2.97 2.72 gp5 protein MSMEG_9588 5.12 2.36 0.00 0.31 2.83 3.14 2.66 hypothetical protein MSMEG_2199 5.09 2.35 0.01 1.00 2.87 2.60 1.10 hypothetical protein MSMEG_3164 5.05 2.34 0.00 0.03 3.9<		5.94	2.57	0.00	0.34	3.14	2.86	1.70	hypothetical protein
MSMEG_5092 5.64 2.50 0.02 1.00 2.75 3.28 1.29 hypothetical protein MSMEG_5135 5.55 2.47 0.00 0.08 2.68 2.21 202 hypothetical protein MSMEG_5095 5.36 2.42 0.42 1.00 -1.89 3.58 0.70 tRNA-Gly MSMEG_1337 5.34 2.42 0.41 1.00 -1.14 3.87 0.78 tRNA-Thr MSMEG_1337 5.34 2.42 0.41 1.00 -1.14 3.87 0.78 tRNA-Thr MSMEG_1363 5.30 2.41 0.00 0.02 3.42 3.11 2.53 hypothetical protein MSMEG_1868 5.09 2.35 0.01 1.00 2.87 2.60 1.10 hypothetical protein hypothetical protein MSMEG_1868 5.09 2.35 0.01 1.00 2.44 2.46 3.82 hypothetical protein MSMEG_1564 5.05 2.34 0.04 1.00	MSMEG_3579	5.79	2.53	0.00	0.13	3.65	3.05	2.48	transmembrane protein
MSMEG_5135 5.55 2.47 0.00 0.08 2.68 2.21 2.02 hypothetical protein MSMEG_5087 5.36 2.42 0.09 1.00 -1.89 3.58 0.70 tRNA-Gly MSMEG_5090 5.36 2.42 0.00 0.13 3.11 2.72 1.92 hypothetical protein MSMEG_1337 5.34 2.42 0.41 1.00 -1.14 3.87 0.78 tRNA-Thr MSMEG_3163 5.30 2.41 0.00 0.02 3.42 3.11 2.53 hypothetical protein MSMEG_5958 5.12 2.36 0.00 0.31 2.83 3.14 2.66 hypothetical protein MSMEG_1868 5.09 2.35 0.01 1.00 2.87 2.60 1.10 hypothetical protein MSMEG_1869 5.05 2.34 0.04 1.00 2.44 2.46 3.82 hypothetical protein MSMEG_3557 5.06 2.34 0.0 0.03 2.99	MSMEG_5459	5.67	2.50	0.00	0.56	2.10	1.74	1.97	hypothetical protein
MSMEG_5535	MSMEG_5092	5.64	2.50	0.02	1.00	2.75	3.28	1.29	hypothetical protein
MSMEG_0677 5.36 2.42 0.42 1.00 -1.89 3.58 0.70 tRNA-Gly MSMEG_1337 5.34 2.42 0.00 0.13 3.11 2.72 1.92 hypothetical protein MSMEG_1337 5.34 2.42 0.41 1.00 -1.14 3.87 0.78 tRNA-Thr MSMEG_2149 5.32 2.41 0.00 0.02 3.42 3.11 2.53 hypothetical protein MSMEG_3163 5.30 2.41 0.00 0.08 3.68 2.97 2.72 gp55 protein MSMEG_1868 5.09 2.35 0.01 1.00 2.87 2.60 1.10 hypothetical protein	MSMEG_5135	5.55	2.47	0.00	0.08	2.68	2.21	2.02	hypothetical protein
MSMEG_5090 5.36 2.42 0.00 0.13 3.11 2.72 1.92 hypothetical protein MSMEG_1337 5.34 2.42 0.41 1.00 -1.14 3.87 0.78 tRNA-Thr MSMEG_1363 5.30 2.41 0.00 0.08 3.68 2.97 2.72 3by pothetical protein MSMEG_5958 5.12 2.36 0.00 0.31 2.83 3.14 2.66 1.10 hypothetical protein MSMEG_1868 5.09 2.35 0.01 1.00 2.87 2.60 1.10 hypothetical protein hypothetical protein MSMEG_199 5.09 2.35 0.00 0.33 3.26 2.50 2.14 hypothetical protein hypothetical protein MSMEG_3578 5.06 2.34 0.00 0.03 2.99 3.07 2.32 hypothetical protein MSMEG_3578 4.95 2.31 0.05 1.26 3.31 0.00 tRNA-Lys MSMEG_9501 4.94 2.30 <td>_</td> <td>5.44</td> <td>2.44</td> <td>0.09</td> <td>1.00</td> <td>3.36</td> <td>2.49</td> <td>0.48</td> <td>hypothetical protein</td>	_	5.44	2.44	0.09	1.00	3.36	2.49	0.48	hypothetical protein
MSMEG_1337	_								
MSMEG_2149 5.32 2.41 0.00 0.02 3.42 3.11 2.53 hypothetical protein MSMEG_3163 5.30 2.41 0.00 0.08 3.68 2.97 2.72 gp55 protein MSMEG_5958 5.12 2.36 0.00 0.31 2.83 3.14 2.66 hypothetical protein MSMEG_1868 5.09 2.35 0.01 1.00 2.87 2.60 1.10 hypothetical protein MSMEG_2199 5.09 2.35 0.00 0.33 3.26 2.50 2.14 hypothetical protein MSMEG_3558 5.06 2.34 0.04 1.00 2.44 2.46 3.82 hypothetical protein MSMEG_4746 5.04 2.33 0.50 1.00 -5.30 3.30 0.01 tRNA-Vs MSMEG_2833 4.96 2.31 0.45 1.00 -1.21 3.31 0.00 tRNA-Val MSMEG_3578 4.95 2.31 0.00 0.41 2.80 2.68	_								
MSMEG_3163 5.30 2.41 0.00 0.08 3.68 2.97 2.72 gp55 protein MSMEG_5958 5.12 2.36 0.00 0.31 2.83 3.14 2.66 hypothetical protein MSMEG_1868 5.09 2.35 0.01 1.00 2.87 2.60 1.10 hypothetical protein MSMEG_1999 5.09 2.35 0.00 0.33 3.26 2.50 2.14 hypothetical protein MSMEG_3164 5.05 2.34 0.00 0.03 2.99 3.07 2.32 hypothetical protein MSMEG_3164 5.05 2.34 0.00 0.03 2.99 3.07 2.32 hypothetical protein MSMEG_3164 5.05 2.34 0.00 0.03 2.99 3.07 2.32 hypothetical protein MSMEG_3164 5.05 2.34 0.00 0.03 2.99 3.07 2.32 hypothetical protein MSMEG_3183 4.96 2.31 0.00 0.03 2.9	_								
MSMEG_5958 5.12 2.36 0.00 0.31 2.83 3.14 2.66 hypothetical protein MSMEG_1868 5.09 2.35 0.01 1.00 2.87 2.60 1.10 hypothetical protein MSMEG_2199 5.09 2.35 0.00 0.33 3.26 2.50 2.14 hypothetical protein MSMEG_5558 5.06 2.34 0.04 1.00 2.44 2.46 3.82 hypothetical protein MSMEG_3164 5.05 2.34 0.00 0.03 2.99 3.07 2.32 hypothetical protein MSMEG_3164 5.05 2.34 0.00 0.03 2.99 3.07 2.32 hypothetical protein MSMEG_2476 5.04 2.33 0.50 1.00 -1.21 3.31 0.00 tRNA-Lys MSMEG_3578 4.95 2.31 0.00 0.08 2.84 2.39 1.99 cyclase MSMEG_3577 4.93 2.30 0.00 0.21 2.80 <									
MSMEG_1868 5.09 2.35 0.01 1.00 2.87 2.60 1.10 hypothetical protein MSMEG_2199 5.09 2.35 0.00 0.33 3.26 2.50 2.14 hypothetical protein MSMEG_5558 5.06 2.34 0.04 1.00 2.44 2.46 3.82 MSMEG_3164 5.05 2.34 0.00 0.03 2.99 3.07 2.32 hypothetical protein MSMEG_4746 5.04 2.33 0.50 1.00 -5.30 3.30 0.01 tRNA-Lys MSMEG_2833 4.96 2.31 0.45 1.00 -1.21 3.31 0.00 tRNA-Val MSMEG_3578 4.95 2.31 0.00 0.08 2.84 2.39 1.99 tRNA-Val MSMEG_5091 4.94 2.30 0.00 0.21 2.05 2.08 1.70 calpastatin calpastatin MSMEG_1860 4.82 4.80 2.26 0.00 0.13 2.20 2.2	_								
MSMEG_2199 5.09 2.35 0.00 0.33 3.26 2.50 2.14 hypothetical protein MSMEG_5558 5.06 2.34 0.04 1.00 2.44 2.46 3.82 hypothetical protein MSMEG_3164 5.05 2.34 0.00 0.03 2.99 3.07 2.32 hypothetical protein MSMEG_4746 5.04 2.33 0.50 1.00 -5.30 3.30 0.01 tRNA-Us MSMEG_3578 4.95 2.31 0.00 0.08 2.84 2.39 1.99 cyclase MSMEG_5091 4.94 2.30 0.00 0.41 2.80 2.68 1.44 hypothetical protein MSMEG_3577 4.93 2.30 0.00 0.41 2.80 2.68 1.70 calpastatin MSMEG_1860 4.92 2.30 0.00 0.34 2.47 2.56 1.76 O-antigen polymerase MSMEG_1404 4.73 2.24 0.05 1.00 3.29 2.15 <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>									
MSMEG_5558 5.06 2.34 0.04 1.00 2.44 2.46 3.82 hypothetical protein MSMEG_3164 5.05 2.34 0.00 0.03 2.99 3.07 2.32 hypothetical protein MSMEG_4746 5.04 2.33 0.50 1.00 -5.30 3.30 0.01 tRNA-Lys MSMEG_2833 4.96 2.31 0.45 1.00 -1.21 3.31 0.00 tRNA-Val MSMEG_5578 4.95 2.31 0.00 0.41 2.80 2.68 1.44 hypothetical protein MSMEG_5091 4.94 2.30 0.00 0.41 2.80 2.68 1.70 calpastatin MSMEG_5960 4.92 2.30 0.00 0.34 2.47 2.56 1.76 O-antigen polymerase MSMEG_1082 4.80 2.26 0.00 0.13 2.20 2.25 2.62 immunogenic protein MPT63 MSMEG_1746 4.72 2.24 0.55 1.00 0.68 <td< td=""><td>_</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></td<>	_								
MSMEG_3164 5.05 2.34 0.00 0.03 2.99 3.07 2.32 hypothetical protein MSMEG_4746 5.04 2.33 0.50 1.00 -5.30 3.30 0.01 tRNA-Lys MSMEG_2833 4.96 2.31 0.45 1.00 -1.21 3.31 0.00 tRNA-Val MSMEG_3578 4.95 2.31 0.00 0.08 2.84 2.39 1.99 cyclase MSMEG_5091 4.94 2.30 0.00 0.41 2.80 2.68 1.44 hypothetical protein MSMEG_5577 4.93 2.30 0.00 0.21 2.05 2.08 1.70 calpastatin MSMEG_5960 4.92 2.30 0.00 0.34 2.47 2.56 1.76 O-antigen polymerase MSMEG_10828 4.80 2.26 0.00 0.13 2.20 2.25 2.62 immunogenic protein MPTG3 MSMEG_1746 4.72 2.24 0.55 1.00 0.68 0.51	_								
MSMEG_4746 5.04 2.33 0.50 1.00 -5.30 3.30 0.01 tRNA-Lys MSMEG_2833 4.96 2.31 0.45 1.00 -1.21 3.31 0.00 tRNA-Val MSMEG_3578 4.95 2.31 0.00 0.08 2.84 2.39 1.99 cyclase MSMEG_5091 4.94 2.30 0.00 0.41 2.80 2.68 1.44 hypothetical protein MSMEG_3577 4.93 2.30 0.00 0.21 2.05 2.08 1.70 calpastatin MSMEG_5960 4.92 2.30 0.00 0.34 2.47 2.56 1.76 O-antigen polymerase MSMEG_10828 4.80 2.26 0.00 0.13 2.20 2.25 2.62 immunogenic protein MPTG3 MSMEG_1746 4.72 2.24 0.55 1.00 0.68 0.51 3.90 6-hydroxy-D-nicotine oxidase MSMEG_9384 4.63 2.21 0.00 0.99 3.37 2.7									
MSMEG_2833 4.96 2.31 0.45 1.00 -1.21 3.31 0.00 tRNA-Val MSMEG_3578 4.95 2.31 0.00 0.08 2.84 2.39 1.99 cyclase MSMEG_5091 4.94 2.30 0.00 0.41 2.80 2.68 1.44 hypothetical protein MSMEG_5777 4.93 2.30 0.00 0.21 2.05 2.08 1.70 calpastatin MSMEG_5960 4.92 2.30 0.00 0.34 2.47 2.56 1.76 O-antigen polymerase MSMEG_0828 4.80 2.26 0.00 0.13 2.20 2.25 2.62 immunogenic protein MPT63 MSMEG_1746 4.73 2.24 0.55 1.00 0.68 0.51 3.90 6-hydroxy-D-nicotine oxidase MSMEG_1965 4.70 2.23 0.45 1.00 -3.34 3.42 0.67 tRNA-Wet MSMEG_9375 4.59 2.20 0.37 1.00 0.30 3.55	_								
MSMEG_3578 4.95 2.31 0.00 0.08 2.84 2.39 1.99 cyclase MSMEG_5091 4.94 2.30 0.00 0.41 2.80 2.68 1.44 hypothetical protein MSMEG_3577 4.93 2.30 0.00 0.21 2.05 2.08 1.70 calpastatin MSMEG_5960 4.92 2.30 0.00 0.34 2.47 2.56 1.76 O-antigen polymerase MSMEG_0828 4.80 2.26 0.00 0.13 2.20 2.25 2.62 immunogenic protein MPT63 MSMEG_1746 4.73 2.24 0.55 1.00 3.29 2.15 1.86 IS1096, tnpA protein MSMEG_1965 4.70 2.23 0.45 1.00 0.68 0.51 3.90 6-hydroxy-D-nicotine exidase MSMEG_9384 4.63 2.21 0.00 0.09 3.37 2.79 2.37 glucose-1-phosphate thymidylyltransferase MSMEG_3755 4.59 2.20 0.37 1.00<	_								
MSMEG_5091 4.94 2.30 0.00 0.41 2.80 2.68 1.44 hypothetical protein MSMEG_3577 4.93 2.30 0.00 0.21 2.05 2.08 1.70 calpastatin MSMEG_5960 4.92 2.30 0.00 0.34 2.47 2.56 1.76 O-antigen polymerase MSMEG_0828 4.80 2.26 0.00 0.13 2.20 2.25 2.62 immunogenic protein MPT63 MSMEG_1404 4.73 2.24 0.03 1.00 3.29 2.15 1.86 IS1096, tnpA protein MSMEG_1746 4.72 2.24 0.55 1.00 0.68 0.51 3.90 6-hydroxy-D-nicotine oxidase MSMEG_1965 4.70 2.23 0.45 1.00 -3.34 3.42 0.67 tRNA-Met MSMEG_3755 4.59 2.20 0.37 1.00 0.30 3.55 0.33 5S ribosomal RNA MSMEG_5134 4.48 2.16 0.00 0.39 1.65 </td <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>									
MSMEG_3577 4.93 2.30 0.00 0.21 2.05 2.08 1.70 calpastatin MSMEG_5960 4.92 2.30 0.00 0.34 2.47 2.56 1.76 O-antigen polymerase MSMEG_0828 4.80 2.26 0.00 0.13 2.20 2.25 2.62 immunogenic protein MPT63 MSMEG_1404 4.73 2.24 0.03 1.00 3.29 2.15 1.86 IS1096, tnpA protein MSMEG_1746 4.72 2.24 0.55 1.00 0.68 0.51 3.90 6-hydroxy-D-nicotine oxidase MSMEG_1965 4.70 2.23 0.45 1.00 -3.34 3.42 0.67 tRNA-Met MSMEG_0384 4.63 2.21 0.00 0.09 3.37 2.79 2.37 glucose-1-phosphate thymidylyltransferase MSMEG_3755 4.59 2.20 0.37 1.00 0.30 3.55 0.33 55 ribosomal RNA MSMEG_5134 4.48 2.16 0.00 0.39 <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>									
MSMEG_5960 4.92 2.30 0.00 0.34 2.47 2.56 1.76 O-antigen polymerase immunogenic protein MPT63 MSMEG_1828 4.80 2.26 0.00 0.13 2.20 2.25 2.62 immunogenic protein MPT63 MSMEG_1404 4.73 2.24 0.03 1.00 3.29 2.15 1.86 IS1096, tnpA protein MSMEG_1746 4.72 2.24 0.55 1.00 0.68 0.51 3.90 6-hydroxy-D-nicotine oxidase MSMEG_1965 4.70 2.23 0.45 1.00 -3.34 3.42 0.67 tRNA-Met MSMEG_0384 4.63 2.21 0.00 0.09 3.37 2.79 2.37 glucose-1-phosphate thymidylyltransferase MSMEG_3755 4.59 2.20 0.37 1.00 0.30 3.55 0.33 Sr ribosomal RNA MSMEG_5134 4.48 2.16 0.00 0.39 1.65 2.02 1.14 hypothetical protein									
MSMEG_0828 4.80 2.26 0.00 0.13 2.20 2.25 2.62 immunogenic protein MPT63 MSMEG_1404 4.73 2.24 0.03 1.00 3.29 2.15 1.86 IS1096, tnpA protein MSMEG_1746 4.72 2.24 0.55 1.00 0.68 0.51 3.90 6-hydroxy-D-nicotine oxidase MSMEG_1965 4.70 2.23 0.45 1.00 -3.34 3.42 0.67 tRNA-Met MSMEG_0384 4.63 2.21 0.00 0.09 3.37 2.79 2.37 glucose-1-phosphate thymidylyltransferase MSMEG_3755 4.59 2.20 0.37 1.00 0.30 3.55 0.33 5S ribosomal RNA MSMEG_1312 4.49 2.17 0.02 1.00 2.03 2.51 0.85 DUF2510 domain-containing protein MSMEG_5134 4.48 2.16 0.00 0.39 1.65 2.02 1.14 hypothetical protein									
MSMEG_1746 4.72 2.24 0.55 1.00 0.68 0.51 3.90 6-hydroxy-D-nicotine oxidase MSMEG_1965 4.70 2.23 0.45 1.00 -3.34 3.42 0.67 tRNA-Met MSMEG_0384 4.63 2.21 0.00 0.09 3.37 2.79 2.37 glucose-1-phosphate thymidylyltransferase MSMEG_3755 4.59 2.20 0.37 1.00 0.30 3.55 0.33 5S ribosomal RNA MSMEG_1312 4.49 2.17 0.02 1.00 2.03 2.51 0.85 DUF2510 domain-containing protein MSMEG_5134 4.48 2.16 0.00 0.39 1.65 2.02 1.14 hypothetical protein		4.80	2.26	0.00	0.13	2.20	2.25	2.62	immunogenic protein MPT63
MSMEG_1965 4.70 2.23 0.45 1.00 -3.34 3.42 0.67 tRNA-Met MSMEG_0384 4.63 2.21 0.00 0.09 3.37 2.79 2.37 glucose-1-phosphate thymidylyltransferase MSMEG_3755 4.59 2.20 0.37 1.00 0.30 3.55 0.33 5S ribosomal RNA MSMEG_1312 4.49 2.17 0.02 1.00 2.03 2.51 0.85 DUF2510 domain-containing protein MSMEG_5134 4.48 2.16 0.00 0.39 1.65 2.02 1.14 hypothetical protein	MSMEG_1404	4.73	2.24	0.03	1.00	3.29	2.15	1.86	IS1096, tnpA protein
MSMEG_0384 4.63 2.21 0.00 0.09 3.37 2.79 2.37 glucose-1-phosphate thymidylyltransferase MSMEG_3755 4.59 2.20 0.37 1.00 0.30 3.55 0.33 5S ribosomal RNA MSMEG_1312 4.49 2.17 0.02 1.00 2.03 2.51 0.85 DUF2510 domain-containing protein MSMEG_5134 4.48 2.16 0.00 0.39 1.65 2.02 1.14 hypothetical protein	MSMEG_1746	4.72	2.24	0.55	1.00	0.68	0.51	3.90	6-hydroxy-D-nicotine oxidase
MSMEG_3755 4.59 2.20 0.37 1.00 0.30 3.55 0.33 5S ribosomal RNA MSMEG_1312 4.49 2.17 0.02 1.00 2.03 2.51 0.85 DUF2510 domain-containing protein MSMEG_5134 4.48 2.16 0.00 0.39 1.65 2.02 1.14 hypothetical protein									
MSMEG_1312 4.49 2.17 0.02 1.00 2.03 2.51 0.85 DUF2510 domain-containing protein hypothetical protein MSMEG_5134 4.48 2.16 0.00 0.39 1.65 2.02 1.14 hypothetical protein	_								
MSMEG_5134 4.48 2.16 0.00 0.39 1.65 2.02 1.14 hypothetical protein									
	MSMEG_5134	4.48	2.16	0.00	0.39	1.65	2.02	1.14	1 22

(continued on next page)

Table 3 (continuea)								
MSMEG_5133	4.42	2.15	80.0	1.00	0.99	2.43	0.93	hypothetical protein
MSMEG_2836	4.34	2.12	0.49	1.00	-5.94	3.34	0.21	tRNA-Val
MSMEG_0200	4.32	2.11	0.02	1.00	2.84	2.96	1.18	hypothetical protein
MSMEG_2570	4.17	2.06	0.01	1.00	1.73	1.10	1.92	xanthine/uracil permease
MSMEG_6580	4.14	2.05	0.00	0.53	1.93	1.52	2.59	transcriptional regulator family protein
MSMEG_5425	4.03	2.01	0.36	1.00	0.32	3.48	0.65	tRNA-GIn
MSMEG_3955	0.23	-2.10	0.27	1.00	-0.46	0.17	0.18	Nitroreductase domain-containing protein
MSMEG_0621	0.23	-2.12	0.21	1.00	0.21	-1.08	-0.43	low molecular weight protein antigen 7
MSMEG_3951	0.22	-2.16	0.29	1.00	-1.71	0.46	1.19	hypothetical protein
MSMEG_0522	0.22	-2.21	0.19	1.00	-3.71	-2.99	-2.80	pp24 protein
MSMEG_3937	0.21	-2.25	0.31	1.00	-0.87	0.89	1.59	Urease subunit alpha
MSMEG_3946	0.21	-2.29	0.17	1.00	-2.24	-0.84	0.57	transmembrane protein
MSMEG_3929	0.20	-2.32	0.27	1.00	-1.38	-0.16	2.95	[NiFe] hydrogenase subunit delta
MSMEG_3954	0.18	-2.44	0.28	1.00	0.32	0.52	1.34	trehalose 6-phosphate phosphorylase
MSMEG_3930	0.18	-2.47	0.27	1.00	-0.53	0.32	2.32	[NiFe] hydrogenase subunit gamma
MSMEG_3931	0.15	-2.70	0.24	1.00	-1.06	0.09	2.21	[NiFe] hydrogenase subunit beta
MSMEG_3936	0.15	-2.74	0.24	1.00	-0.38	0.26	1.39	universal stress protein family protein
MSMEG_3953	0.14	-2.84	0.23	1.00	-2.33	0.31	1.51	hypothetical protein
MSMEG_3939	0.14	-2.88	0.27	1.00	0.17	0.85	0.53	universal stress protein family protein
MSMEG_3932	0.14	-2.88	0.22	1.00	-1.10	0.09	1.68	14 kDa antigen
MSMEG_3940	0.11	-3.16	0.22	1.00	-0.83	0.31	0.57	universal stress protein family protein
MSMEG_3934	0.10	-3.39	0.18	1.00	-1.44	-0.41	0.77	phosphoenolpyruvate synthase




Fig. 3. RNA-seq reads in the region of *lsr2* (MSMEG_6092): EB1 has an IS1096 insertion eliminating *lsr2* transcription; EB2, has a different IS1096 insertion; EB3, showing insertion of a T that causes a frameshift; EB4, a small minority of reads show the same nucleotide insertion as in EB3; wt mc²155, a small minority of reads show the same nucleotide insertion as in EB3.

Our triple mutant EB1 ($\Delta pknL/\Delta MSMEG_4242/\Delta lsr2$) was shown by MS to have several lipid species that are not present in the parent mc²155, probably LOS-A, possibly LOS-C and perhaps GPLs. It was previously shown that the synthesis of these LOS, which were present in the original M. smegmatis ATCC607 but lost in the transformation competent M. smegmatis mc²155, depends upon the PKS protein encoded by $MSMEG_4727$ (Etienne et al., 2009). In strains EB1, 2 and 3 -- the smooth colony mutants with inactivated lsr2 genes, the transcription of $MSMEG_4727$ was several times greater than in the parent strain (Table 3), as previously reported for other lsr2 mutant strains (Colangeli et al., 2007; Kolodziej et al., 2021). When $MSMEG_4727$ was eliminated, the strain regained the rough morphology of the parent mc²155, formed strong biofilms and had reduced motility, although still 50% greater than the original mc²155 progenitor. Similar results were recently reported for another lsr2 mutant(Kolodziej et al., 2021).

Lsr2 is a two-domain protein composed of an N-terminal dimerization domain and a C-terminal DNA-binding domain. The crystal structure of the truncated N-terminal dimer domain (Summers et al., 2012) revealed an elongated molecule made up of a single four-stranded betasheet with two helices on one side. The carboxylate groups of the two Asp35, which are replaced by Alanine in some of the smooth mutants, are completely exposed to the solvent at each extremity (Figure S4). The N-terminal domain can also promote higher-order Lsr2 assemblies, providing a mechanism for the role of Lsr2 in the compaction and physical protection of DNA (Colangeli et al., 2009). Since Asp35 is directly engaged in dimer-dimer electrostatic contacts leading to higher oligomers, the Asp35-Ala substitution might limit the ability of Lsr2 to form these higher-order DNA binding assemblies.

Lsr2 binds to multiple DNA targets, but when phosphorylated by PknB on threonine 112, its ability to bind to DNA is abrogated (Alqaseer et al., 2019). Thus, phosphorylation of Lsr2 would lead to increased ex-




Fig. 4. Thin layer chromatography. Anomalous lipid bands in *lsr2* mutant strains were eliminated either by inactivating the MSMEG_4727 (PKS5) gene (A), or complementing with a plasmid containing an intact copy of *lsr2* (B). C. Mass spectrometry of wt mc²155 and EB1 total lipids, or D. fraction 8.


pression of the genes it represses, such as MSMEG_4727 (Kocíncová et al., 2008; Kolodziej et al., 2021). Perhaps PknL can also phosphorylate Lsr2, but as PknL cannot autophosphorylate (Baer et al., 2014), there may be a phosphorylation cascade whereby PknB phosphorylates PknL, which in turn phosphorylates Lsr2 (Fig. 6 A-C). However, there is currently no experimental evidence that PknL can phosphorylate Lsr2, which may only be phosphorylated by PknB (Fig. 6E).

PknL has been shown to phosphorylate the protein encoded by the adjacent and divergently transcribed, putative transcriptional regulator Rv2175c, the *M. tuberculosis* equivalent of MSMEG_4242, which then loses its ability to bind DNA (Molle and Kremer, 2010). In an alternative model, the unphosphorylated MSMEG_4242/Rv2175c represses the expression of LOS and GPL synthesis and the repression is relieved when this transcriptional regulator is phosphorylated by PknL, which in turn is phosphorylated by PknB (Fig. 6D). The phosphorylation of Rv2175c or Lsr2 would abrogate their ability to bind DNA and repress transcription, which would induce the expression of the lipid-producing genes they regulate. This is consistent with other studies showing that phosphorylation by PknB has a negative effect on protein function, which also results in decreased synthesis and transport of mycolates to the envelope (Le et al., 2020; Kolodziej et al., 2021).

An intriguing finding from this study was that strains lacking *pknL* and MSMEG_4242 accumulate mutations or insertions in *lsr2* at a very high frequency, $\sim 10^{-2}$. Presumably this is because the lack of PknL

somehow causes stress in the bacteria, which is reflected in the increased transcription of tnpA, the IS1096 transposase. The rough colony pknL/MSMEG 4242 mutants did not show altered lipid bands by TLC but had a reduced sliding motility that was aberrant, jagged and asymmetric (Fig. 2F), as well as weak, delayed formation of biofilms (Fig. 2E), suggesting that PknL is involved with the synthesis of cell envelope components. Other viable M. smegmatis variants, including ATCC607, also lack sliding motility but show a much lower frequency of insertions into lsr2. However, the very abnormal motility in the rough ΔpknL/ΔMSMEG 4242 mutants may reflect severe, unknown alterations in the cell envelope. Perhaps the LOS or other lipid species produced by lsr2 inactivation somehow compensate for these undefined defects. It is interesting that in EB4, the $\Delta pknL/\Delta MSMEG_4242$ strain with integrated pknL/MSMEG 4242, a frameshifting nucleotide deletion was seen in very few reads. The EB4 mutant was originally smooth but changed its phenotype with passaging and the RNA-seq was performed after many passages. This could indicate that the defect that led to the lsr2 mutations was alleviated by the integrated complementing genes, or alternatively, possible contamination with the parent strain. This same frameshifting mutation was seen in reads from EB3, in a minority of reads in the parent strain and was even present in three reads from EB1.

The phenotypic changes produced by the inactivation of *lsr2* suggest a phase change from a strain that forms biofilms and has moderate



- The bars show Std. Dev; *, p<0.05; **, p<0.005 (T-test)
- +++ Mature floating biofilm
- ++ Mature biofilm
- Slow formation of biofilm
- Abnormal biofilm
- No biofilm

Fig. 5. Summary of colony morphology, biofilm formation and spreading motility. Colony morphology of the strains whose genotypes are shown on the right. The height of the bars in the histogram indicate the average diameter of the sliding motility halos of three independent experiments, with duplicates of each strain in each of the three experiments. One experiment is shown in Fig. 3G. Asterisks (*) indicate a significant difference in the diameter of the halo: *, P < 0.05; **, P < 0.005 The biofilms formed by each strain are indicated by +'s or -'s according to the key shown below the colonies, based on three experiments, each with duplicates, as in Fig. 3F.

motility, to one that does not form biofilms, has high motility and is therefore more likely to spread rather than attach to a surface. The lipid components of the outer cell envelope seem to spontaneously vary in M. smegmatis, giving rise to many variants (Kocíncová et al., 2008), which may be a mechanism for survival in different environments (Kolodziej et al., 2021) (Wang et al., 2008). In M. abscessus, the rough colony strains lack GPLs present in smooth morphotypes and are more virulent in animal models, but the smooth M. abscessus variants are perhaps better suited for survival in environmental niches(Roux et al., 2016; Bernut et al., 2014; Howard et al., 2006). In contrast with M. smegmatis, though, deletion of lsr2 in M. abscessus has no effect on the GPL profile, at least under laboratory growth conditions (Le Moigne et al., 2019). Similarly, it was recently suggested that rough morphotypes of M. kansasii might be an adaptation favorable for human pathogenicity (Luo et al., 2021). Perhaps the smooth M. canettii, or its recent ancestors, existed in an environmental niche but lost their LOS when they evolved into the rough, aggregative pathogen M. tuberculosis (Boritsch et al., 2016), which is not known to grow outside of mammalian hosts. Although we do not know exactly how PknL functions, nor exactly which lipid components determine sliding motility, biofilm formation and colony morphotype, this study suggests that both Lsr2 and PknL are involved in regulating components of the outer cell wall of M. smegmatis, but this regulation seems complex. Likely the conserved transcriptional regulator adjacent to PknL (MSMEG_4242/Rv2175c), as well as additional regulators such as other nucleoid-associated proteins (Ghosh et al., 2013) or other STPK could also be involved in the synthesis(Le et al., 2020) and export(Le et al., 2020; Pérez et al., 2006; Melly et al., 2021) of the components of the cell envelope that determine these complex phenotypes.

4. Methods


4.1. Construction and selection of mutants.

Vector pUC19, modified to eliminate the BamHI site, was used to clone a 4450 bp fragment amplified from a boiled lysate of mc^2155 with primers PknLXbaIFw and PknLXbaIRv (Table S1). This fragment in-

cluded MSMEG_4242, MSMEG_4243 (*pknL*) and 1500 pb on either side of these genes. This construct was then cut with BamHI to eliminate the 5′ end of MSMEG_4242, the intergenic region and half of MSMEG_4243 (*pknL*), including the kinase motif, and then religated with a kanamycin resistance cassette cut from pUC4K with BamHI. The entire insert, with the Kan cassette, was cut with XbaI and ligated into pPR27.

The pPR27-ΔpknL/ΔMsmeg4242::kan^R construct and control vector pPR27 and modified pPR17-pJV53 were electroporated into M. smegmatis mc2155, and also M. smegmatis mc2155 strains containing chromosomally integrated pYUB412int plasmids with MSMEG_4242, MSMEG_4243(pknL), or both genes. The electroporated strains were then plated onto 7H10-OAD (Oleic Acid, Albumin Dextrose) with kanamycin and gentamycin and incubated at 32 °C. for 4-5 days (Pelicic et al., 1997). Colonies from these plates were inoculated into 5 ml of 7H9-OAD-kanamycin (25 μ g/ml) and grown until saturation for 4 days at 32 °C. From these liquid cultures, 5 ul (first expt.) or 100 ul (second expt.) were plated onto 7H10-OAD-kan (25 µg/ml) with 10% sucrose and grown at 39 °C. until colonies appeared (10 – 15 days). All of the colonies that appeared were grown in 7H9-OAD-Kan (25 μg/ml) at 39° C (first experiment) or 37 °C (second experiment), and the second crossover event was confirmed by the inability to grow on 7H10-OAD plates with gentamycin 5 µg/ml.

To construct knockouts of single genes, first plasmid pUC119 was cut with PstI and filled-in with Klenow (NEB) to make pUC2P, and separately the HindIII site was similarly eliminated to make pUC2H. Two 1500 bp fragments, one containing MSMEG_4241 and MSMEG_4243 (*pknL*) and the other MSMEG_4242 and MSMEG_4244 (Fig. 1Ba) were amplified from an *M. smegmatis* boiled lysate with primers 1KOFw4242-1KORv4242, 2KOFw4242-2KORv4242 and 1KOFw4243-1KORv4243, 2KOFw4243-2KORv4243 (Table S1). The amplified fragments containing MSMEG_4242 were cut with PstI, eliminating most of this gene, then religated and inserted into the XbaI site of pUC3P to make pUCKO4242 (Fig. 1Bb). The amplified fragments containing MSMEG_4243 (*pknL*), were cut with HindIII, religated and then inserted into the XbaI site of pUC2H to make pUCKO4243 (Fig. 1Bc). The *aph* kanamycin resistance cassette was then inserted into the PstI site of pUCKO4242 and



(caption on next page)




Fig. 6. Hypothetical schemes of how PknL might function to produce the phenotype seen in the mutant strains. While the loss of *lsr2* is responsible for several of the phenotypes in the EB series smooth mutant strains, the rough mutants have altered motility and biofilm formation despite having an intact *lsr2* gene. The gene or genes responsible for the phenotypes of the rough strains are unknown. PknB phosphorylates PknL and PknL phosphorylates Lsr2, which abolishes its ability to bind DNA and thus relieves the repression of LOS-A and GPL synthesis. In an *lsr2* mutated strain there is unrepressed synthesis of LOS-A and GPLs PknL phosphorylates Lsr2, but in a *pknL* Knockout, the unphosphorylated Lsr2 represses LOS & GPL synthesis. In an alternative scheme, PknB phosphorylates PknL (MSMEG_4243) and PknL phosphorylates the putative transcriptional regulator encoded by the adjacent gene MSMEG_4242, which then loses its ability to bind DNA and repress gene transcription, resulting in the synthesis of GPL and LOS-A. Another possibility is that PknB phosphorylates Lsr2 directly, without PknL serving as a phosphorylation cascade intermediate.

the HindIII site of pUCK04243 (Fig. 1B d & e). The plasmids were transformed into $E.\ coli\ XL1B$ lue and plated on agar with kanamycin and carbenicillin. The fragments MSMEG_4242::Kan^R and MSMEG_KO4243::Kan^R were then cut from the pUC plasmids and ligated into vector pPR27 and electroporated into $M.\ smegmatis\ mc^2155$ for allelic exchange, as described above.

The *lsr2* mutant strain was the kind gift of Roberto Colangeli, along with *lsr2* containing, complementing plasmid pMP161.

4.2. Confirmation of mutants.

Gentamycin sensitive colonies were grown in 7H9-OAD-Kan and 1 ml of culture was centrifuged, resuspended in 150 ul sterile distilled water and boiled for 10 min. From this boiled lysate, 10 ul were used in a PCR amplification with primers Msmeg_4242pknLsmeg412Fw y

pknLsmeg412Rv (Table S1), and the product was sequenced in CeSAAN (IVIC, Caracas, Venezuela) and subjected to restriction analysis. The elimination of the two genes was also subsequently confirmed by RNA-seq.

4.3. Cloning of complementing integrative plasmids.

Vector pYUB412int was transformed into *E.coli* K12 ER2925 (*dam*) in order to use the *BclI* cloning site, and grown in LB broth with carbenicillin 50 ug/ml. The amplified fragments containing MSMEG_4242, MSMEG_4243(*pknL*), or both genes (Table S1) were ligated into the pYUBint vector using the *BclI*, or *PacI* sites, and then electroporated into mc^2 155 (Snapper et al., 1990) and plated onto 7H10-OAD-Hygromicin 50 µg/ml, and the presence of the inserts verified by PCR amplification and restriction digests.

4.4. Ziehl-Neelsen staining

Ziehl-Neelsen staining was performed using the traditional method. Slides spread with 10 μl of a bacterial suspension were fixed over a flame. They were then covered with phenol fucsin, heated over a flame three times during a period of ten minutes, and then washed with distilled water. The slides were then covered with acid alcohol for 3 min and again washed with distilled water. Finally, the slides were covered with methylene blue for one minute, washed, left to air dry and examined with a 100X objective microscope.

4.5. Measurements of bacilli length.

From exponential phase cultures (DO $_{600}=0,8-1$), 10 μ l were placed on glass microscope slides and air dried. After adding 2 μ l of glycerol, the slides were examined with a Nikon E-600 microscope using a 100X oil immersion objective. DIC (Differential Interference Contrast) images were taken, blinded to strain identification, with a digital Hamamatsu camera using the Methamorph program. The lengths of 50 bacilli of each strain were measured with Image-J software.

4.6. Motility assay.

Colonies were inoculated into 7H9 with 10% OAD and 0.05% Tween 80 and grown to mid log phase (D.O $_{600\mathrm{nm}}=0.4-0.6$). A toothpick was dipped into the culture, excess drops were allowed to fall off, and it was stabbed into the center of a Petri dish containing 7H9 media without glycerol and 0.3% agarose. The diameter of the motility halo was measured after 2 days of incubation at 37 °C.

4.7. Biofilm assays

Biofilm formation was assessed by inoculating 20 ul of a bacterial culture (OD $_{600}$, 0.8 to 1.0) onto the wells of a 6 well plate, each containing 4 ml of M63 salts supplemented with 10% glucose, 1 mM CaCl $_2$ and 1 mM MgSO $_4$ and then incubated without shaking at 30 °C for 5 days.

4.8. Determination of rifampicin sensitivity

The strains were grown in 7H9-OAD at 37 °C. until reaching log phase (1–5 \times 108 CFU/ml), diluted 1:100 and then 10 ul of the dilution was inoculated onto 2 mls of 7H10-OAD with rifampicin 32 or 64 $\mu g/$ mL in a 24 well plate and incubated at 37 °C for 3 to 5 days until confluent growth was observed. Each strain was tested in triplicate.

4.9. RNA-seg analysis

The strains were grown in 7H9-OADC at 37 °C, RNA was isolated, reverse transcribed and sequenced as previously described (Solans et al., 2014). Illumina reads were mapped against the *M. smegmatis* mc²155 reference sequence (NCBI RefSeq: NC_008596.1) with bowtie2 (Langmead and Salzberg, 2012) v.2.0.0-beta7. Gene counts (based on the NC_008596.1 annotation) were obtained with *htseq-count* tool (https://htseq.readthedocs.io/en/release_0.11.1/count.html). To minimize count bias from overlapping genes, overlapping gene regions (except for nested genes) were excluded and the option '-m intersection-strict' was used. Differential gene expression analysis was done with the DESeq package (Anders and Huber, 2010) v.1.12.1. Alignments were visualized in IGV viewer(Thorvaldsdottir et al., 2013). The RNA-seq data is available under BioProject reference PRJNA735510.

To look for new IS1096 insertions, the transcriptome of each mutant was assembled *de novo* using SPAdes v.3.15.2 with the "--rna" option (Bushmanova et al., 2019). Transcripts containing the IS1096 sequence were identified using BLASTn and the IS1096' flanking sequences were blasted against the mc²155 reference genome to infer their location.

IS1096 insertion sites from the transcriptomes were compared to the known sites in the reference genome (Wang et al., 2008) to determine whether their location corresponded to a known IS1096 insertion site in the reference genome or constituted a new insertion site unique to the mutant.

4.10. Lipid extractions and (HP)TLC analyses

Bacteria were cultured to Log growth phase in 7H9-OADC, collected by centrifugation and washed twice with PBS. Apolar and polar lipid fractions were extracted from 50 mg of wet-weight bacterial pellet and the polar lipid fraction analysed by thin-layer liquid chromatography as previously described (Besra, 1998). The total extractable lipids were recovered from wet bacterial pellets by three successive extractions using distinct mixtures of CHCl₃:CH₃OH (1:2, 1:1 and 2:1, v/v). The fractions were pooled, washed with water and dried. For thin-layer chromatography (TLC) analysis, equivalent weights of total lipid fraction from each strain were spotted on silica gel 60 plates (Merck), which were developed either in CHCl₃:CH₃OH (9:1, v/v) or in CHCl₃:CH₃OH:H₂O (65:25:4, v/v/v), as indicated. Compounds were revealed by spraying with 0.2% (w/v) anthrone in concentrated H₂SO₄ followed by heating at 100 °C.

The relative abundance of the different types of lipids from each strain was determined by loading a fixed amount (5 μ g) of lipid mixture onto a high-performance TLC (HPTLC) silica gel 60 plate (Merck) with a Camag ATS4 apparatus. The plate was developed in appropriate organic solvent mixtures using a Camag ADC2 device and stained by immersion in 10% (w/v) CuSO₄ (in H₃PO₄:CH₃OH:H₂O, 8:5:87, v/v/v) with a Camag CID3 apparatus, followed by heating at 150 °C for 20 min. Lipids were quantified by absorption measurement at 400 nm with a Camag Scanner 3 device using Wincats software.

4.11. MALDI-TOF MS and NMR spectroscopy

Matrix assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) and MS/MS analyses were performed in the positive ionization and reflectron mode, using the 5800 MALDI-TOF/TOF Analyzer (Applied Biosystems/ABsciex) equipped with a Nd:YAG laser (349 nm wavelength). MS and MS/MS spectra were acquired with a total of 2,500 shots at a fixed laser intensity of 4,000 (instrument-specific units) and 400-Hz pulse rate for MS, and a total of 5000 shots at a fixed laser intensity of 6000 (instrument-specific units) and 1000-Hz pulse rate for MS/MS. For MS/MS data acquisition, the fragmentation of selected precursor ions was performed at a collision energy of 1 kV using air as collision gaz. Lipid samples were dissolved in chloroform and were directly spotted onto the target plate as $0.5~\mu l$ droplets, followed by the addition of 0.5 µl of matrix solution {10 mg/ ml of 2,5-dihydroxybenzoic acid (Sigma-Aldrich) in CHCl3/CH3OH (1:1, v/v)}. Samples were allowed to crystallize at room temperature. MS data were acquired using the instrument default calibration.

CRediT authorship contribution statement

Báez-Ramírez: Conceptualization, Methodol-Estalina Formal analysis, Investigation, Visualization, Writing ogy, review & editing. Luis Querales: Methodology, Formal **Andres** analysis, Investigation, Visualization. Carlos Aranaga: Methodology, Formal analysis, Investigation, Visu-Writing editing. alization, review & Gustavo López: Methodology, Investigation, Visualiza-**Formal** analysis, Elba Methodology, tion. **Guerrero:** Formal analysis, Inves-Conceptualizatigation, Visualization. Laurent Kremer: Methodology, tion, Resources, Supervision, Funding acqui-Visualization, sition. Supervision, Writing review editing. Séverine Carrère-Kremer: Methodology, Investiga-

Albertus Viljoen: Methodology, Formal analysis, Investigation, Visualization, Writing original draft, Writing review & editing. Mamadou Daffé: Methodology, mal analysis, Resources, Visualization, Supervi-Françoise Laval: Methodology, Formal analysis, sion. vestigation, Visualization. Stewart Cole: Resources, Supervision, Funding acquisition, Writing review editing. Andrej Benjak: Methodology, Software, Formal analy-Visualization, original sis, Investigation, Writing Writing draft, review & editing. Pedro Alzari: Formal Writing analysis, Funding acquisition, original editing. Gwenaëlle Andrédraft, review & Writing Methodology, Investigation. Bill Jacobs: Re-Leroux: Supervision, Funding acquisition, sources. Writing review editing. Vilcheze: Methodology, Catherine Formal & Writing Investigation, review editanalysis, Methodology, Howard Takiff: Conceptualization, Foring. analysis. Visualization, Supervision, Investimal Resources. Funding gation, Data Writing curation. acquisition, Writing draft, review & editing, Project adminoriginal istration.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.tcsw.2021.100060.

References

- Molle V, Kremer L. 2010. Division and cell envelope regulation by Ser/Thr phosphorylation: Mycobacterium shows the way. Molecular microbiology 75:1064-77 Kang CM, Abbott DW, Park ST, Dascher CC, Cantley LC, Husson RN. 2005. The Mycobacterium tuberculosis serine/threonine kinases PknA and PknB: substrate identification and regulation of cell shape. Genes Dev 19:1692-704
- Narayan, A., Sachdeva, P., Sharma, K., Saini, A.K., Tyagi, A.K., Singh, Y., 2007. Serine threonine protein kinases of mycobacterial genus: phylogeny to function. Physiological genomics 29 (1), 66–75.
- Wehenkel, A., Bellinzoni, M., Graña, M., Duran, R., Villarino, A., Fernandez, P., Andre-Leroux, G., England, P., Takiff, H., Cerveñansky, C., Cole, S.T., Alzari, P.M., 2008. Mycobacterial Ser/Thr protein kinases and phosphatases: physiological roles and therapeutic potential. Biochimica et biophysica acta 1784 (1), 193–202.
- Refaya, A.K., Sharma, D., Kumar, V., Bisht, D., Narayanan, S., 2016. A Serine/threonine kinase PknL, is involved in the adaptive response of Mycobacterium tuberculosis. Microbiol Res 190, 1–11.
- Naz, S., Singh, Y., Nandicoori, V.K., 2021. Deletion of serine/threonine-protein kinase pknL from Mycobacterium tuberculosis reduces the efficacy of isoniazid and ethambutol. Tuberculosis (Edinb) 128, 102066
- Canova, M.J., Veyron-Churlet, R., Zanella-Cleon, I., Cohen-Gonsaud, M., Cozzone, A.J., Becchi, M., Kremer, L., Molle, V., 2008. The Mycobacterium tuberculosis serine/threonine kinase Pknl. phosphorylates Rv2175c: mass spectrometric profiling of the activation loop phosphorylation sites and their role in the recruitment of Rv2175c. Proteomics 8 (3), 521–533.
- Cohen-Gonsaud, M., Barthe, P., Canova, M.J., Stagier-Simon, C., Kremer, L., Roumestand, C., Molle, V., 2009. The Mycobacterium tuberculosis Ser/Thr kinase substrate Rv2175c is a DNA-binding protein regulated by phosphorylation. The Journal of biological chemistry 284 (29), 19290–19300.
- Av-Gay, Y., Everett, M., 2000. The eukaryotic-like Ser/Thr protein kinases of Mycobacterium tuberculosis. Trends Microbiol 8 (5), 238–244.
- Bellinzoni, M., Wehenkel, A.M., Durán, R., Alzari, P.M., 2019. Novel mechanistic insights into physiological signaling pathways mediated by mycobacterial Ser/Thr protein kinases. Microbes Infect 21 (5–6), 222–229.
- Baer, C.E., Iavarone, A.T., Alber, T., Sassetti, C.M., 2014. Biochemical and spatial coincidence in the provisional Ser/Thr protein kinase interaction network of Mycobacterium tuberculosis. J Biol Chem 289 (30), 20422–20433.
- Schultz C, Niebisch A, Schwaiger A, Viets U, Metzger S, Bramkamp M, Bott M. 2009. Genetic and biochemical analysis of the serine/threonine protein kinases PknA, PknB, PknG and PknL of Corynebacterium glutamicum: evidence for non-essentiality and for phosphorylation of OdhI and FtsZ by multiple kinases. Molecular microbiology 74:724-41

- Kocíncová, D., Singh, A.K., Beretti, J.-L., Ren, H., Euphrasie, D., Liu, J., Daffé, M., Etienne, G., Reyrat, J.-M., 2008. Spontaneous transposition of IS1096 or ISMsm3 leads to glycopeptidolipid overproduction and affects surface properties in Mycobacterium smeematis. Tuberculosis (Edinb) 88 (5). 390–398.
- Recht, J., Kolter, R., 2001. Glycopeptidolipid acetylation affects sliding motility and biofilm formation in Mycobacterium smegmatis. J Bacteriol 183 (19), 5718–5724.
- Chen JM, Ren H, Shaw JE, Wang YJ, Li M, Leung AS, Tran V, Berbenetz NM, Kocincova D, Yip CM, Reyrat JM, Liu J. 2008. Lsr2 of Mycobacterium tuberculosis is a DNA-bridging protein. Nucleic Acids Res 36:2123-35
- Gordon, B.R.G., Li, Y., Wang, L., Sintsova, A., van Bakel, H., Tian, S., Navarre, W.W., Xia, B., Liu, J., 2010. Lsr2 is a nucleoid-associated protein that targets AT-rich sequences and virulence genes in Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 107 (11), 5154–5159.
- Etienne, G., Laval, F., Villeneuve, C., Dinadayala, P., Abouwarda, A., Zerbib, D., Galamba, A., Daffe, M., 2005. The cell envelope structure and properties of Mycobacterium smegmatis mc(2)155: is there a clue for the unique transformability of the strain?. Microbiology (Reading) 151, 2075–2086.
- Etienne G, Malaga W, Laval F, Lemassu A, Guilhot C, Daffe M. 2009. Identification of the polyketide synthase involved in the biosynthesis of the surface-exposed lipooligosaccharides in mycobacteria. J Bacteriol 191:2613-21.
- Colangeli R, Helb D, Vilcheze C, Hazbon MH, Lee CG, Safi H, Sayers B, Sardone I, Jones MB, Fleischmann RD, Peterson SN, Jacobs WR, Jr., Alland D. 2007. Transcriptional regulation of multi-drug tolerance and antibiotic-induced responses by the histone-like protein Lsr2 in M. tuberculosis. PLoS Pathog 3:e87.
- Boritsch, E.C., Frigui, W., Cascioferro, A., Malaga, W., Etienne, G., Laval, F., Pawlik, A., Le Chevalier, F., Orgeur, M., Ma, L., Bouchier, C., Stinear, T.P., Supply, P., Majlessi, L., Daffe, M., Guilhot, C., Brosch, R., 2016. pks5-recombination-mediated surface remodelling in Mycobacterium tuberculosis emergence. Nat Microbiol 1, 15019.
- Kolodziej M, Lebkowski T, Plocinski P, Holowka J, Pasciak M, Wojtas B, Bury K, Konieczny I, Dziadek J, Zakrzewska-Czerwinska J. 20Lsr2 and Its Novel Paralogue Mediate the Adjustment of Mycobacterium smegmatis to Unfavorable Environmental Conditions. mSphere 6.
- Le, N.-H., Locard-Paulet, M., Stella, A., Tomas, N., Molle, V., Burlet-Schiltz, O., Daffé, M., Marrakchi, H., 2020. The protein kinase PknB negatively regulates biosynthesis and trafficking of mycolic acids in mycobacteria. J Lipid Res 61 (8), 1180–1191.
- Zeng, J., Platig, J., Cheng, T.Y., Ahmed, S., Skaf, Y., Potluri, L.P., Schwartz, D., Steen, H., Moody, D.B., Husson, R.N., 2020. Protein kinases PknA and PknB independently and coordinately regulate essential Mycobacterium tuberculosis physiologies and antimicrobial susceptibility. PLoS Pathog 16, e1008452.
- Kolodziej, M., Trojanowski, D., Bury, K., Holowka, J., Matysik, W., Kakolewska, H., Feddersen, H., Giacomelli, G., Konieczny, I., Bramkamp, M., Zakrzewska-Czerwinska, J., 2021. Lsr2, a nucleoid-associated protein influencing mycobacterial cell cycle. Sci Rep 11. 2910.
- Alqaseer, K., Turapov, O., Barthe, P., Jagatia, H., De Visch, A., Roumestand, C., Wegrzyn, M., Bartek, I.L., Voskuil, M.I., O'Hare, H.M., Ajuh, P., Bottrill, A.R., Witney, A.A., Cohen-Gonsaud, M., Waddell, S.J., Mukamolova, G.V., 2019. Protein kinase B controls Mycobacterium tuberculosis growth via phosphorylation of the transcriptional regulator Lsr2 at threonine 112. Mol Microbiol 112 (6), 1847–1862.
- Arora, K., Whiteford, D.C., Lau-Bonilla, D., Davitt, C.M., Dahl, J.L., 2008. Inactivation of lsr2 results in a hypermotile phenotype in Mycobacterium smegmatis. J Bacteriol 190 (12), 4291–4300.
- Chen, J.M., German, G.J., Alexander, D.C., Ren, H., Tan, T., Liu, J., 2006. Roles of Lsr2 in colony morphology and biofilm formation of Mycobacterium smegmatis. J Bacteriol 188 (2), 633–641.
- Recht, J., Martínez, A., Torello, S., Kolter, R., 2000. Genetic analysis of sliding motility in Mycobacterium smegmatis. J Bacteriol 182 (15), 4348–4351.
- Snapper, S.B., Melton, R.E., Mustafa, S., Kieser, T., Jr, W.R.J., 1990. Isolation and characterization of efficient plasmid transformation mutants of Mycobacterium smegmatis. Mol Microbiol 4 (11), 1911–1919.
- Summers, E.L., Meindl, K., Uson, I., Mitra, A.K., Radjainia, M., Colangeli, R., Alland, D., Arcus, V.L., 2012. The structure of the oligomerization domain of Lsr2 from Mycobacterium tuberculosis reveals a mechanism for chromosome organization and protection. PLoS One 7, e38542.
- Colangeli, R., Haq, A., Arcus, V.L., Summers, E., Magliozzo, R.S., McBride, A., Mitra, A.K., Radjainia, M., Khajo, A., Jacobs, W.R., Salgame, P., Alland, D., 2009. The multifunctional histone-like protein Lsr2 protects mycobacteria against reactive oxygen intermediates. Proc Natl Acad Sci U S A 106 (11), 4414–4418.
- Wang, X.-M., Galamba, A., Warner, D.F., Soetaert, K., Merkel, J.S., Kalai, M., Bifani, P., Lefèvre, P., Mizrahi, V., Content, J., 2008. IS1096-mediated DNA rearrangements play a key role in genome evolution of Mycobacterium smegmatis. Tuberculosis (Edinb) 88 (5), 399–409.
- Roux, A.L., Viljoen, A., Bah, A., Simeone, R., Bernut, A., Laencina, L., Deramaudt, T., Rottman, M., Gaillard, J.L., Majlessi, L., Brosch, R., Girard-Misguich, F., Vergne, I., de Chastellier, C., Kremer, L., Herrmann, J.L., 2016. The distinct fate of smooth and rough Mycobacterium abscessus variants inside macrophages. Open Biol 6.
- Bernut, A., Herrmann, J.L., Kissa, K., Dubremetz, J.F., Gaillard, J.L., Lutfalla, G., Kremer, L., 2014. Mycobacterium abscessus cording prevents phagocytosis and promotes abscess formation. Proc Natl Acad Sci U S A 111, E943-52.
- Howard, S.T., Rhoades, E., Recht, J., Pang, X., Alsup, A., Kolter, R., Lyons, C.R., Byrd, T.F., 2006. Spontaneous reversion of Mycobacterium abscessus from a smooth to a rough morphotype is associated with reduced expression of glycopeptidolipid and reacquisition of an invasive phenotype. Microbiology (Reading) 152, 1581–1590.
- Le Moigne, V., Bernut, A., Cortes, M., Viljoen, A., Dupont, C., Pawlik, A., Gaillard, J.L., Misguich, F., Cremazy, F., Kremer, L., Herrmann, J.L., 2019. Lsr2 Is an Important Determinant of Intracellular Growth and Virulence in Mycobacterium abscessus. Front Microbiol 10, 905.

Luo, T., Xu, P., Zhang, Y., Porter, J.L., Ghanem, M., Liu, Q., Jiang, Y., Li, J., Miao, Q., Hu, B., Howden, B.P., Fyfe, J.A.M., Globan, M., He, W., He, P., Wang, Y., Liu, H., Takiff, H.E., Zhao, Y., Chen, X., Pan, Q., Behr, M.A., Stinear, T.P., Gao, Q., 2021. Population genomics provides insights into the evolution and adaptation to humans of the waterborne pathogen Mycobacterium kansasii. Nat Commun 12, 2491.
Ghosh, S., Indi, S.S., Nagaraja, V., 2013. Regulation of lipid biosynthesis, sliding motility,

- Ghosh, S., Indi, S.S., Nagaraja, V., 2013. Regulation of lipid biosynthesis, sliding motility, and biofilm formation by a membrane-anchored nucleoid-associated protein of Mycobacterium tuberculosis. J Bacteriol 195 (8), 1769–1778.
- Pérez, J., Garcia, R., Bach, H., de Waard, J.H., Jacobs, W.R., Av-Gay, Y., Bubis, J., Takiff, H.E., 2006. Mycobacterium tuberculosis transporter MmpL7 is a potential substrate for kinase PknD. Biochemical and biophysical research communications 348 (1), 6–12.
- Melly, G.C., Stokas, H., Davidson, P.M., Roma, J.S., Rhodes, H.L., Purdy, G.E., 2021. Identification of residues important for M. tuberculosis MmpL11 function reveals that function is modulated by phosphorylation in the C-terminal domain. Mol Microbiol 115, 208–221.
- Solans, L., Gonzalo-Asensio, J., Sala, C., Benjak, A., Uplekar, S., Rougemont, J., Guilhot, C., Malaga, W., Martin, C., Cole, S.T., 2014. The PhoP-dependent ncRNA Mcr7 modulates the TAT secretion system in Mycobacterium tuberculosis. PLoS Pathog 10,

e1004183.

- Langmead, B., Salzberg, S.L., 2012. Fast gapped-read alignment with Bowtie 2. Nat Methods 9 (4), 357–359.
- Anders, S., Huber, W., 2010. Differential expression analysis for sequence count data. Genome Biol 11, R106.
- Thorvaldsdottir, H., Robinson, J.T., Mesirov, J.P., 2013. Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Brief Bioinform 14 (2), 178–192.
- Bushmanova, E., Antipov, D., Lapidus, A., Prjibelski, A.D., 2019. rnaSPAdes: a de novo transcriptome assembler and its application to RNA-Seq data. Gigascience 8.
- Besra GS. 1998. Preparation of Cell-Wall Fractions from Mycobacteria, p 91-108, Mycobacteria Protocols vol 101. Humana Press.
- Pelicic, V., Jackson, M., Reyrat, J.-M., Jacobs, W.R., Gicquel, B., Guilhot, C., 1997. Efficient allelic exchange and transposon mutagenesis in Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 94 (20), 10955–10960.